5vyh › Citations

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.

Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong WP, Andres EL, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS
Proc Natl Acad Sci U S A 114 E7348-E7357 (2017)
Related entries: 5vzr, 5w9h, 5w9i, 5w9j, 5w9k, 5w9l, 5w9m, 5w9n, 5w9o, 5w9p

Cited: 611 times
EuropePMC logo PMID: 28807998

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus that since its emergence in 2012 has caused outbreaks in human populations with case-fatality rates of ∼36%. As in other coronaviruses, the spike (S) glycoprotein of MERS-CoV mediates receptor recognition and membrane fusion and is the primary target of the humoral immune response during infection. Here we use structure-based design to develop a generalizable strategy for retaining coronavirus S proteins in the antigenically optimal prefusion conformation and demonstrate that our engineered immunogen is able to elicit high neutralizing antibody titers against MERS-CoV. We also determined high-resolution structures of the trimeric MERS-CoV S ectodomain in complex with G4, a stem-directed neutralizing antibody. The structures reveal that G4 recognizes a glycosylated loop that is variable among coronaviruses and they define four conformational states of the trimer wherein each receptor-binding domain is either tightly packed at the membrane-distal apex or rotated into a receptor-accessible conformation. Our studies suggest a potential mechanism for fusion initiation through sequential receptor-binding events and provide a foundation for the structure-based design of coronavirus vaccines.

Articles - 5vyh mentioned but not cited (4)

  1. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong WP, Andres EL, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS. Proc Natl Acad Sci U S A 114 E7348-E7357 (2017)
  2. Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein. Zhou H, Chen Y, Zhang S, Niu P, Qin K, Jia W, Huang B, Zhang S, Lan J, Zhang L, Tan W, Wang X. Nat Commun 10 3068 (2019)
  3. Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD. Wang N, Rosen O, Wang L, Turner HL, Stevens LJ, Corbett KS, Bowman CA, Pallesen J, Shi W, Zhang Y, Leung K, Kirchdoerfer RN, Becker MM, Denison MR, Chappell JD, Ward AB, Graham BS, McLellan JS. Cell Rep 28 3395-3405.e6 (2019)
  4. Pharmacophore-Based Virtual Screening, Quantum Mechanics Calculations, and Molecular Dynamics Simulation Approaches Identified Potential Natural Antiviral Drug Candidates against MERS-CoV S1-NTD. Bouback TA, Pokhrel S, Albeshri A, Aljohani AM, Samad A, Alam R, Hossen MS, Al-Ghamdi K, Talukder MEK, Ahammad F, Qadri I, Simal-Gandara J. Molecules 26 4961 (2021)


Reviews citing this publication (175)

  1. SARS-CoV-2 vaccines in development. Krammer F. Nature 586 516-527 (2020)
  2. Adaptive immunity to SARS-CoV-2 and COVID-19. Sette A, Crotty S. Cell 184 861-880 (2021)
  3. SARS-CoV-2 Vaccines: Status Report. Amanat F, Krammer F. Immunity 52 583-589 (2020)
  4. Viral targets for vaccines against COVID-19. Dai L, Gao GF. Nat Rev Immunol 21 73-82 (2021)
  5. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. Yang Y, Peng F, Wang R, Yange, Guan K, Jiang T, Xu G, Sun J, Chang C. J Autoimmun 109 102434 (2020)
  6. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. NPJ Vaccines 6 28 (2021)
  7. Exploitation of glycosylation in enveloped virus pathobiology. Watanabe Y, Bowden TA, Wilson IA, Crispin M. Biochim Biophys Acta Gen Subj 1863 1480-1497 (2019)
  8. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. Wang N, Shang J, Jiang S, Du L. Front Microbiol 11 298 (2020)
  9. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. Front Immunol 11 576622 (2020)
  10. Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design. Xia X. Viruses 13 109 (2021)
  11. Progress and Prospects on Vaccine Development against SARS-CoV-2. Zhang J, Zeng H, Gu J, Li H, Zheng L, Zou Q. Vaccines (Basel) 8 E153 (2020)
  12. COVID-19 vaccines: rapid development, implications, challenges and future prospects. Kashte S, Gulbake A, El-Amin Iii SF, Gupta A. Hum Cell 34 711-733 (2021)
  13. Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus. Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS. Front Microbiol 10 1781 (2019)
  14. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Bettini E, Locci M. Vaccines (Basel) 9 147 (2021)
  15. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. Mendonça SA, Lorincz R, Boucher P, Curiel DT. NPJ Vaccines 6 97 (2021)
  16. Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines. Rey FA, Lok SM. Cell 172 1319-1334 (2018)
  17. Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Sternberg A, Naujokat C. Life Sci 257 118056 (2020)
  18. COVID-19: Coronavirus Vaccine Development Updates. Zhao J, Zhao S, Ou J, Zhang J, Lan W, Guan W, Wu X, Yan Y, Zhao W, Wu J, Chodosh J, Zhang Q. Front Immunol 11 602256 (2020)
  19. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Bok K, Sitar S, Graham BS, Mascola JR. Immunity 54 1636-1651 (2021)
  20. Structure-Based Vaccine Antigen Design. Graham BS, Gilman MSA, McLellan JS. Annu Rev Med 70 91-104 (2019)
  21. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Pollet J, Chen WH, Strych U. Adv Drug Deliv Rev 170 71-82 (2021)
  22. Advances in COVID-19 mRNA vaccine development. Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, Wu X, Liu J, Zhao D, Li Y. Signal Transduct Target Ther 7 94 (2022)
  23. COVID-19 vaccine: where are we now and where should we go? Soleimanpour S, Yaghoubi A. Expert Rev Vaccines 20 23-44 (2021)
  24. Prospects for a MERS-CoV spike vaccine. Zhou Y, Jiang S, Du L. Expert Rev Vaccines 17 677-686 (2018)
  25. Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery. Ho W, Gao M, Li F, Li Z, Zhang XQ, Xu X. Adv Healthc Mater 10 e2001812 (2021)
  26. Approaches and Challenges in SARS-CoV-2 Vaccine Development. Dagotto G, Yu J, Barouch DH. Cell Host Microbe 28 364-370 (2020)
  27. Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain. Zhou Y, Yang Y, Huang J, Jiang S, Du L. Viruses 11 E60 (2019)
  28. The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses. Tse LV, Meganck RM, Graham RL, Baric RS. Front Microbiol 11 658 (2020)
  29. Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19. Andryukov BG. AIMS Microbiol 6 280-304 (2020)
  30. The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines. Morais P, Adachi H, Yu YT. Front Cell Dev Biol 9 789427 (2021)
  31. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. Mudgal R, Nehul S, Tomar S. Hum Vaccin Immunother 16 2921-2931 (2020)
  32. COVID-19 mRNA vaccines: Platforms and current developments. Szabó GT, Mahiny AJ, Vlatkovic I. Mol Ther 30 1850-1868 (2022)
  33. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand? Chakraborty S, Mallajosyula V, Tato CM, Tan GS, Wang TT. Adv Drug Deliv Rev 172 314-338 (2021)
  34. Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production. Zhao X, Chen H, Wang H. Front Mol Biosci 8 629873 (2021)
  35. Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. Zhou YW, Xie Y, Tang LS, Pu D, Zhu YJ, Liu JY, Ma XL. Signal Transduct Target Ther 6 317 (2021)
  36. Antibodies and vaccines against Middle East respiratory syndrome coronavirus. Xu J, Jia W, Wang P, Zhang S, Shi X, Wang X, Zhang L. Emerg Microbes Infect 8 841-856 (2019)
  37. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. Chi WY, Li YD, Huang HC, Chan TEH, Chow SY, Su JH, Ferrall L, Hung CF, Wu TC. J Biomed Sci 29 82 (2022)
  38. Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2. Kaur N, Singh R, Dar Z, Bijarnia RK, Dhingra N, Kaur T. Infect Genet Evol 89 104490 (2021)
  39. Recent Aspects on the Pathogenesis Mechanism, Animal Models and Novel Therapeutic Interventions for Middle East Respiratory Syndrome Coronavirus Infections. Skariyachan S, Challapilli SB, Packirisamy S, Kumargowda ST, Sridhar VS. Front Microbiol 10 569 (2019)
  40. Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Rijkers GT, Weterings N, Obregon-Henao A, Lepolder M, Dutt TS, van Overveld FJ, Henao-Tamayo M. Vaccines (Basel) 9 848 (2021)
  41. COVID-19 Vaccine in Pregnant and Lactating Women: A Review of Existing Evidence and Practice Guidelines. Garg I, Shekhar R, Sheikh AB, Pal S. Infect Dis Rep 13 685-699 (2021)
  42. Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism. Schindewolf C, Menachery VD. Viruses 11 E74 (2019)
  43. Virus vaccines: proteins prefer prolines. Sanders RW, Moore JP. Cell Host Microbe 29 327-333 (2021)
  44. Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev RA. Adv Drug Deliv Rev 170 113-141 (2021)
  45. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Batty CJ, Heise MT, Bachelder EM, Ainslie KM. Adv Drug Deliv Rev 169 168-189 (2021)
  46. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. Granados-Riveron JT, Aquino-Jarquin G. Biomed Pharmacother 142 111953 (2021)
  47. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Finkelstein MT, Mermelstein AG, Parker Miller E, Seth PC, Stancofski ED, Fera D. Viruses 13 134 (2021)
  48. Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Mengist HM, Kombe Kombe AJ, Mekonnen D, Abebaw A, Getachew M, Jin T. Semin Immunol 55 101533 (2021)
  49. Point-of-Care Diagnostics of COVID-19: From Current Work to Future Perspectives. Hussein HA, Hassan RYA, Chino M, Febbraio F. Sensors (Basel) 20 E4289 (2020)
  50. The success of SARS-CoV-2 vaccines and challenges ahead. Subbarao K. Cell Host Microbe 29 1111-1123 (2021)
  51. Antibodies to combat viral infections: development strategies and progress. Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Nat Rev Drug Discov 21 676-696 (2022)
  52. COVID-19 mRNA vaccines. Huang Q, Zeng J, Yan J. J Genet Genomics 48 107-114 (2021)
  53. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype. Pascolo S. Viruses 13 270 (2021)
  54. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects. Arashkia A, Jalilvand S, Mohajel N, Afchangi A, Azadmanesh K, Salehi-Vaziri M, Fazlalipour M, Pouriayevali MH, Jalali T, Mousavi Nasab SD, Roohvand F, Shoja Z, SARS CoV-2 Rapid Response Team of Pasteur Institute of Iran (PII). Rev Med Virol 31 e2183 (2021)
  55. Minireview of progress in the structural study of SARS-CoV-2 proteins. Zhu G, Zhu C, Zhu Y, Sun F. Curr Res Microb Sci 1 53-61 (2020)
  56. SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells. Cannalire R, Stefanelli I, Cerchia C, Beccari AR, Pelliccia S, Summa V. Int J Mol Sci 21 E5707 (2020)
  57. The way of SARS-CoV-2 vaccine development: success and challenges. Dong Y, Dai T, Wang B, Zhang L, Zeng LH, Huang J, Yan H, Zhang L, Zhou F. Signal Transduct Target Ther 6 387 (2021)
  58. HIV mRNA Vaccines-Progress and Future Paths. Mu Z, Haynes BF, Cain DW. Vaccines (Basel) 9 134 (2021)
  59. Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2. Sabanovic B, Piva F, Cecati M, Giulietti M. Biology (Basel) 10 94 (2021)
  60. Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. Torrents de la Peña A, Sanders RW. Retrovirology 15 63 (2018)
  61. Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins. Li YH, Hu CY, Wu NP, Yao HP, Li LJ. Engineering (Beijing) 5 940-947 (2019)
  62. Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages. Lee P, Kim CU, Seo SH, Kim DJ. Immune Netw 21 e4 (2021)
  63. Expression and characterization of SARS-CoV-2 spike proteins. Schaub JM, Chou CW, Kuo HC, Javanmardi K, Hsieh CL, Goldsmith J, DiVenere AM, Le KC, Wrapp D, Byrne PO, Hjorth CK, Johnson NV, Ludes-Meyers J, Nguyen AW, Wang N, Lavinder JJ, Ippolito GC, Maynard JA, McLellan JS, Finkelstein IJ. Nat Protoc 16 5339-5356 (2021)
  64. Perspectives in Peptide-Based Vaccination Strategies for Syndrome Coronavirus 2 Pandemic. Di Natale C, La Manna S, De Benedictis I, Brandi P, Marasco D. Front Pharmacol 11 578382 (2020)
  65. The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies. Molaei S, Dadkhah M, Asghariazar V, Karami C, Safarzadeh E. Int Immunopharmacol 92 107051 (2021)
  66. A structural view of the SARS-CoV-2 virus and its assembly. Hardenbrook NJ, Zhang P. Curr Opin Virol 52 123-134 (2022)
  67. Protein engineering strategies for rational immunogen design. Caradonna TM, Schmidt AG. NPJ Vaccines 6 154 (2021)
  68. Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country. Requena D, Médico A, Chacón RD, Ramírez M, Marín-Sánchez O. Front Immunol 11 2008 (2020)
  69. Spike Glycoprotein-Mediated Entry of SARS Coronaviruses. Wang L, Xiang Y. Viruses 12 E1289 (2020)
  70. The Potential Role of Osteopontin and Furin in Worsening Disease Outcomes in COVID-19 Patients with Pre-Existing Diabetes. Adu-Agyeiwaah Y, Grant MB, Obukhov AG. Cells 9 E2528 (2020)
  71. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): State of the Science. Mostafa A, Kandeil A, Shehata M, El Shesheny R, Samy AM, Kayali G, Ali MA. Microorganisms 8 E991 (2020)
  72. Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review. Derking R, Sanders RW. J Int AIDS Soc 24 Suppl 7 e25797 (2021)
  73. Advanced Materials for SARS-CoV-2 Vaccines. Mabrouk MT, Huang WC, Martinez-Sobrido L, Lovell JF. Adv Mater 34 e2107781 (2022)
  74. SARS-CoV-2, Early Entry Events. Chambers JP, Yu J, Valdes JJ, Arulanandam BP. J Pathog 2020 9238696 (2020)
  75. Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. Gieselmann L, Kreer C, Ercanoglu MS, Lehnen N, Zehner M, Schommers P, Potthoff J, Gruell H, Klein F. Nat Protoc 16 3639-3671 (2021)
  76. Biological characteristics and biomarkers of novel SARS-CoV-2 facilitated rapid development and implementation of diagnostic tools and surveillance measures. Ghodake GS, Shinde SK, Kadam AA, Saratale RG, Saratale GD, Syed A, Elgorban AM, Marraiki N, Kim DY. Biosens Bioelectron 177 112969 (2021)
  77. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. Strohl WR, Ku Z, An Z, Carroll SF, Keyt BA, Strohl LM. BioDrugs 36 231-323 (2022)
  78. Promoting versatile vaccine development for emerging pandemics. Monrad JT, Sandbrink JB, Cherian NG. NPJ Vaccines 6 26 (2021)
  79. SARS-CoV-2 Virus-Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response. Queirós-Reis L, Gomes da Silva P, Gonçalves J, Brancale A, Bassetto M, Mesquita JR. Int J Mol Sci 22 10836 (2021)
  80. Structure-based immunogen design-leading the way to the new age of precision vaccines. Sesterhenn F, Bonet J, Correia BE. Curr Opin Struct Biol 51 163-169 (2018)
  81. The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. Machado BAS, Hodel KVS, Fonseca LMDS, Mascarenhas LAB, Andrade LPCDS, Rocha VPC, Soares MBP, Berglund P, Duthie MS, Reed SG, Badaró R. Vaccines (Basel) 9 1345 (2021)
  82. The use of databases, data mining and immunoinformatics in vaccinology: where are we? Hegde NR, Gauthami S, Sampath Kumar HM, Bayry J. Expert Opin Drug Discov 13 117-130 (2018)
  83. Coronavirus in human diseases: Mechanisms and advances in clinical treatment. Lin P, Wang M, Wei Y, Kim T, Wei X. MedComm (2020) 1 270-301 (2020)
  84. PEDV: Insights and Advances into Types, Function, Structure, and Receptor Recognition. Lin F, Zhang H, Li L, Yang Y, Zou X, Chen J, Tang X. Viruses 14 1744 (2022)
  85. Biomedical Science to Tackle the COVID-19 Pandemic: Current Status and Future Perspectives. Zamora-Ledezma C, C DFC, Medina E, Sinche F, Santiago Vispo N, Dahoumane SA, Alexis F. Molecules 25 E4620 (2020)
  86. Cryo-EM Studies of Virus-Antibody Immune Complexes. Li N, Li Z, Fu Y, Cao S. Virol Sin 35 1-13 (2020)
  87. Challenges and Issues of Anti-SARS-CoV-2 Vaccines. Blumental S, Debré P. Front Med (Lausanne) 8 664179 (2021)
  88. SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development: A review. Muhammed Y, Yusuf Nadabo A, Pius M, Sani B, Usman J, Anka Garba N, Mohammed Sani J, Opeyemi Olayanju B, Zeal Bala S, Garba Abdullahi M, Sambo M. Biosaf Health 3 249-263 (2021)
  89. Solutions against emerging infectious and noninfectious human diseases through the application of baculovirus technologies. Targovnik AM, Simonin JA, Mc Callum GJ, Smith I, Cuccovia Warlet FU, Nugnes MV, Miranda MV, Belaich MN. Appl Microbiol Biotechnol 105 8195-8226 (2021)
  90. 50 Years of structural immunology. Wilson IA, Stanfield RL. J Biol Chem 296 100745 (2021)
  91. Layer-By-Layer Nanocoating of Antiviral Polysaccharides on Surfaces to Prevent Coronavirus Infections. Otto DP, de Villiers MM. Molecules 25 E3415 (2020)
  92. Principles and practical applications of structure-based vaccine design. Byrne PO, McLellan JS. Curr Opin Immunol 77 102209 (2022)
  93. Transient Expression of Glycosylated SARS-CoV-2 Antigens in Nicotiana benthamiana. Ruocco V, Strasser R. Plants (Basel) 11 1093 (2022)
  94. Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK. Clin Transl Immunology 10 e1345 (2021)
  95. Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019. Salazar-García M, Acosta-Contreras S, Rodríguez-Martínez G, Cruz-Rangel A, Flores-Alanis A, Patiño-López G, Luna-Pineda VM. Front Microbiol 12 817200 (2021)
  96. SARS-CoV-2-Specific Vaccine Candidates; the Contribution of Structural Vaccinology. Pack SM, Peters PJ. Vaccines (Basel) 10 236 (2022)
  97. VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants. Prates-Syed WA, Chaves LCS, Crema KP, Vuitika L, Lira A, Côrtes N, Kersten V, Guimarães FEG, Sadraeian M, Barroso da Silva FL, Cabral-Marques O, Barbuto JAM, Russo M, Câmara NOS, Cabral-Miranda G. Vaccines (Basel) 9 1409 (2021)
  98. Vaccines against COVID-19: Priority to mRNA-Based Formulations. Pascolo S. Cells 10 2716 (2021)
  99. Viral metagenomics, protein structure, and reverse genetics: Key strategies for investigating coronaviruses. Johnson BA, Graham RL, Menachery VD. Virology 517 30-37 (2018)
  100. An Update on mRNA-Based Viral Vaccines. Jeeva S, Kim KH, Shin CH, Wang BZ, Kang SM. Vaccines (Basel) 9 965 (2021)
  101. Can We AlphaFold Our Way Out of the Next Pandemic? Higgins MK. J Mol Biol 433 167093 (2021)
  102. Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines. Zhou J, Liu Z, Zhang G, Xu W, Xing L, Lu L, Wang Q, Jiang S. J Med Virol 95 e28172 (2023)
  103. Moving from Empirical to Rational Vaccine Design in the 'Omics' Era. Sharma M, Krammer F, García-Sastre A, Tripathi S, Tripathi S. Vaccines (Basel) 7 E89 (2019)
  104. Structural Dynamics and Molecular Evolution of the SARS-CoV-2 Spike Protein. Wolf KA, Kwan JC, Kamil JP. mBio 13 e0203021 (2022)
  105. Antibody-mediated immunity to SARS-CoV-2 spike. Errico JM, Adams LJ, Fremont DH. Adv Immunol 154 1-69 (2022)
  106. Combining structure and genomics to understand antimicrobial resistance. Tunstall T, Portelli S, Phelan J, Clark TG, Ascher DB, Furnham N. Comput Struct Biotechnol J 18 3377-3394 (2020)
  107. Known Cellular and Receptor Interactions of Animal and Human Coronaviruses: A Review. Everest H, Stevenson-Leggett P, Bailey D, Bickerton E, Keep S. Viruses 14 351 (2022)
  108. Legume Lectins with Different Specificities as Potential Glycan Probes for Pathogenic Enveloped Viruses. Barre A, Van Damme EJM, Klonjkowski B, Simplicien M, Sudor J, Benoist H, Rougé P. Cells 11 339 (2022)
  109. Targeting Viral Surface Proteins through Structure-Based Design. Narkhede YB, Gonzalez KJ, Strauch EM. Viruses 13 1320 (2021)
  110. The role of vaccines in the COVID-19 pandemic: what have we learned? Krammer F. Semin Immunopathol (2023)
  111. An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies. Zhang N, Shang J, Li C, Zhou K, Du L. Expert Rev Vaccines 19 817-829 (2020)
  112. Engineering viral genomics and nano-liposomes in microfluidic platforms for patient-specific analysis of SARS-CoV-2 variants. Satta S, Shahabipour F, Gao W, Lentz SR, Perlman S, Ashammakhi N, Hsiai T. Theranostics 12 4779-4790 (2022)
  113. Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited]. Jawalagatti V, Kirthika P, Lee JH. Front Immunol 13 884862 (2022)
  114. Protein engineering responses to the COVID-19 pandemic. Hsieh CL, McLellan JS. Curr Opin Struct Biol 74 102385 (2022)
  115. COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era. Volkan E. Mol Biotechnol 63 885-897 (2021)
  116. Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm. Boni C, Cavazzini D, Bolchi A, Rossi M, Vecchi A, Tiezzi C, Barili V, Fisicaro P, Ferrari C, Ottonello S. Front Immunol 12 730051 (2021)
  117. Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients. Romano E, Pascolo S, Ott P. J Immunother Cancer 9 e002932 (2021)
  118. Nucleic Acid Vaccines against SARS-CoV-2. Liu Y, Ye Q. Vaccines (Basel) 10 1849 (2022)
  119. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Zhang C, Zhou C, Shi L, Liu G. Hum Vaccin Immunother 16 2366-2369 (2020)
  120. Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses. Russell CJ, Hurwitz JL. Viruses 13 1023 (2021)
  121. Structure-Based and Rational Design of a Hepatitis C Virus Vaccine. Guest JD, Pierce BG. Viruses 13 837 (2021)
  122. The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis. Daian E Silva DSO, da Fonseca FG. Vaccines (Basel) 9 1101 (2021)
  123. Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2. Choudhary V, Gupta A, Sharma R, Parmar HS. J Proteins Proteom 12 257-270 (2021)
  124. Vaccine Preventable Zoonotic Diseases: Challenges and Opportunities for Public Health Progress. Carpenter A, Waltenburg MA, Hall A, Kile J, Killerby M, Knust B, Negron M, Nichols M, Wallace RM, Behravesh CB, McQuiston JH, The Vaccine Preventable Zoonotic Disease Working Group. Vaccines (Basel) 10 993 (2022)
  125. Vaccine development and technology for SARS-CoV-2: Current insight. Cattel L, Giordano S, Traina S, Lupia T, Corcione S, Angelone L, La Valle G, De Rosa FG, Cattel F. J Med Virol 94 878-896 (2022)
  126. A Structural View at Vaccine Development against M. tuberculosis. Romano M, Squeglia F, Kramarska E, Barra G, Choi HG, Kim HJ, Ruggiero A, Berisio R. Cells 12 317 (2023)
  127. From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era. Miao G, Chen Z, Cao H, Wu W, Chu X, Liu H, Zhang L, Zhu H, Cai H, Lu X, Shi J, Liu Y, Feng T. Biomed Pharmacother 158 114208 (2023)
  128. Glycan Nanostructures of Human Coronaviruses. Guo W, Lakshminarayanan H, Rodriguez-Palacios A, Salata RA, Xu K, Draz MS. Int J Nanomedicine 16 4813-4830 (2021)
  129. Innate Immune Response and Inflammasome Activation During SARS-CoV-2 Infection. Islamuddin M, Mustfa SA, Ullah SNMN, Omer U, Kato K, Parveen S. Inflammation 45 1849-1863 (2022)
  130. Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies. Choi JA, Kim JO. J Microbiol 60 238-246 (2022)
  131. SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines. Velusamy P, Kiruba K, Su CH, Arun V, Anbu P, Gopinath SCB, Vaseeharan B. J King Saud Univ Sci 33 101648 (2021)
  132. Accelerating clinical trial development in vaccinology: COVID-19 and beyond. Corey L, Miner MD. Curr Opin Immunol 76 102206 (2022)
  133. Application of Traditional Vaccine Development Strategies to SARS-CoV-2. Rando HM, Lordan R, Lee AJ, Naik A, Wellhausen N, Sell E, Kolla L, COVID-19 Review Consortium, Gitter A, Greene CS. mSystems 8 e0092722 (2023)
  134. Broad-spectrum pan-genus and pan-family virus vaccines. Tan CW, Valkenburg SA, Poon LLM, Wang LF. Cell Host Microbe 31 902-916 (2023)
  135. Imaging and visualizing SARS-CoV-2 in a new era for structural biology. Leigh KE, Modis Y. Interface Focus 11 20210019 (2021)
  136. Leveraging deep learning to improve vaccine design. Hederman AP, Ackerman ME. Trends Immunol 44 333-344 (2023)
  137. The Coming of Age of Nucleic Acid Vaccines during COVID-19. Rando HM, Lordan R, Kolla L, Sell E, Lee AJ, Wellhausen N, Naik A, Kamil JP, COVID-19 Review Consortium, Gitter A, Greene CS. mSystems 8 e0092822 (2023)
  138. The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. Qiao S, Zhang S, Ge J, Wang X. FEBS Open Bio 12 1602-1622 (2022)
  139. Three-Dimensional Visualization of Viral Structure, Entry, and Replication Underlying the Spread of SARS-CoV-2. Saville JW, Berezuk AM, Srivastava SS, Subramaniam S. Chem Rev 122 14066-14084 (2022)
  140. Towards Innovative Design and Application of Recombinant Eimeria as a Vaccine Vector. Tang X, Liu X, Suo X. Infect Immun 88 e00861-19 (2020)
  141. Cryo-EM as a powerful tool for drug discovery: recent structural based studies of SARS-CoV-2. Kim HU, Jung HS. Appl Microsc 51 13 (2021)
  142. Laboratory-Based Resources for COVID-19 Diagnostics: Traditional Tools and Novel Technologies. A Perspective of Personalized Medicine. Andryukov BG, Besednova NN, Kuznetsova TA, Fedyanina LN. J Pers Med 11 42 (2021)
  143. Modified mRNA-Based Vaccines Against Coronavirus Disease 2019. Wang AYL. Cell Transplant 31 9636897221090259 (2022)
  144. Neutralizing monoclonal antibodies against highly pathogenic coronaviruses. Xiang R, Wang Y, Wang L, Deng X, Huo S, Jiang S, Yu F. Curr Opin Virol 53 101199 (2022)
  145. New insights on possible vaccine development against SARS-CoV-2. Chaudhry SN, Hazafa A, Mumtaz M, Kalsoom U, Abbas S, Kainaat A, Bilal S, Zafar N, Siddique A, Zafar A. Life Sci 260 118421 (2020)
  146. SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders. Khare S, Niharika, Singh A, Hussain I, Singh NB, Singh S. Appl Biochem Biotechnol 195 1541-1573 (2023)
  147. Spike Glycoprotein Is Central to Coronavirus Pathogenesis-Parallel Between m-CoV and SARS-CoV-2. Saadi F, Pal D, Sarma JD. Ann Neurosci 28 201-218 (2021)
  148. Structural and Biophysical Characterization of the HCV E1E2 Heterodimer for Vaccine Development. Toth EA, Chagas A, Pierce BG, Fuerst TR. Viruses 13 1027 (2021)
  149. Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants. Zhang J, Xia Y, Liu X, Liu G. Bioengineering (Basel) 10 148 (2023)
  150. COVID-19 variants that escape vaccine immunity: Global and Indian context-are more vaccines needed? Deb B, Vilvadrinath R, Goel S. J Biosci 46 112 (2021)
  151. Contributions of single-particle cryoelectron microscopy toward fighting COVID-19. Rapp M, Shapiro L, Frank J. Trends Biochem Sci 47 117-123 (2022)
  152. Global patterns of Middle East respiratory syndrome coronavirus (MERS-CoV) prevalence and seroprevalence in camels: A systematic review and meta-analysis. Islam MM, Khanom H, Farag E, Mim ZT, Naidoo P, Mkhize-Kwitshana ZL, Tibbo M, Islam A, Soares Magalhaes RJ, Hassan MM. One Health 16 100561 (2023)
  153. Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients. Baron F, Canti L, Ariën KK, Kemlin D, Desombere I, Gerbaux M, Pannus P, Beguin Y, Marchant A, Humblet-Baron S. Front Immunol 13 827242 (2022)
  154. On the irrationality of rational design of an HIV vaccine in light of protein intrinsic disorder. Uversky VN. Arch Virol 166 1283-1296 (2021)
  155. Recent Update of COVID-19 Vaccines. Jadaan SA, Khan AW. Adv Pharm Bull 12 219-236 (2022)
  156. Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress. Kovalenko A, Ryabchevskaya E, Evtushenko E, Nikitin N, Karpova O. Int J Mol Sci 24 1701 (2023)
  157. Towards Quantum-Chemical Level Calculations of SARS-CoV-2 Spike Protein Variants of Concern by First Principles Density Functional Theory. Ching WY, Adhikari P, Jawad B, Podgornik R. Biomedicines 11 517 (2023)
  158. Variants of SARS-CoV-2: Influences on the Vaccines' Effectiveness and Possible Strategies to Overcome Their Consequences. Rabaan AA, Al-Ahmed SH, Albayat H, Alwarthan S, Alhajri M, Najim MA, AlShehail BM, Al-Adsani W, Alghadeer A, Abduljabbar WA, Alotaibi N, Alsalman J, Gorab AH, Almaghrabi RS, Zaidan AA, Aldossary S, Alissa M, Alburaiky LM, Alsalim FM, Thakur N, Verma G, Dhawan M. Medicina (Kaunas) 59 507 (2023)
  159. HIV infection and the implication for COVID-19 vaccination. Oyelade T, Raya RP, Latief K. Public Health Chall 1 e14 (2022)
  160. SARS-CoV-2 S Glycoprotein Stabilization Strategies. Pedenko B, Sulbaran G, Guilligay D, Effantin G, Weissenhorn W. Viruses 15 558 (2023)
  161. Stabilisation of Viral Membrane Fusion Proteins in Prefusion Conformation by Structure-Based Design for Structure Determination and Vaccine Development. Ebel H, Benecke T, Vollmer B. Viruses 14 1816 (2022)
  162. Strategies for the Management of Spike Protein-Related Pathology. Halma MTJ, Plothe C, Marik P, Lawrie TA. Microorganisms 11 1308 (2023)
  163. The impact of high-resolution structural data on stemming the COVID-19 pandemic. Cox RM, Plemper RK. Curr Opin Virol 49 127-138 (2021)
  164. Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. Xiao Y, Xu H, Guo W, Zhao Y, Luo Y, Wang M, He Z, Ding Z, Liu J, Deng L, Sha F, Ma X. Mol Biomed 1 16 (2020)
  165. Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to the Coronaviridae and Togaviridae families (Review). Babaeimarzangou SS, Zaker H, Soleimannezhadbari E, Gamchi NS, Kazeminia M, Tarighi S, Seyedian H, Tsatsakis A, Spandidos DA, Margina D. Exp Ther Med 25 42 (2023)
  166. Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. Jiang C, Jiang K, Li X, Zhang N, Zhu W, Meng L, Zhang Y, Lu S. J Pharm Anal 13 1-10 (2023)
  167. Innovation-driven trend shaping COVID-19 vaccine development in China. Zhang Y, Zhao Y, Liang H, Xu Y, Zhou C, Yao Y, Wang H, Yang X. Front Med 17 1096-1116 (2023)
  168. Plant lectins as versatile tools to fight coronavirus outbreaks. Simplicien M, Pério P, Sudor J, Barre A, Benoist H, Van Damme EJM, Rougé P. Glycoconj J 40 109-118 (2023)
  169. Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates. Wang Q, Liu Z. Eur J Med Chem Rep 1 100003 (2021)
  170. Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. Lim HT, Kok BH, Lim CP, Abdul Majeed AB, Leow CY, Leow CH. Biomed Eng Adv 4 100054 (2022)
  171. Structural understanding of SARS-CoV-2 virus entry to host cells. Le K, Kannappan S, Kim T, Lee JH, Lee HR, Kim KK. Front Mol Biosci 10 1288686 (2023)
  172. The Input of Structural Vaccinology in the Search for Vaccines against Bunyaviruses. Serris A. Viruses 13 1766 (2021)
  173. The status of COVID-19 vaccines in India: A review. Jha DK, Pranay K, Samiksha, Kumar A, Yashvardhini N. Vacunas (2023)
  174. Understanding Fc function for rational vaccine design against pathogens. Bowman KA, Kaplonek P, McNamara RP. mBio 15 e0303623 (2024)
  175. [Industrial property and basic research in the genesis of the mRNA vaccine against COVID-19]. Migus A. Bull Acad Natl Med 206 1214-1222 (2022)

Articles citing this publication (432)

  1. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Science 367 1260-1263 (2020)
  2. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Cell 181 281-292.e6 (2020)
  3. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH, mRNA-1273 Study Group. N Engl J Med 383 1920-1931 (2020)
  4. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Şahin U, Gruber WC. N Engl J Med 383 2439-2450 (2020)
  5. A serological assay to detect SARS-CoV-2 seroconversion in humans. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K, Arunkumar GA, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin L, Fierer DS, Lugo LA, Kojic EM, Stoever J, Liu STH, Cunningham-Rundles C, Felgner PL, Moran T, García-Sastre A, Caplivski D, Cheng AC, Kedzierska K, Vapalahti O, Hepojoki JM, Simon V, Krammer F. Nat Med 26 1033-1036 (2020)
  6. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE, Havenar-Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS, Fink K, Veesler D, Corti D. Nature 583 290-295 (2020)
  7. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, Malyutin AG, Sharaf NG, Huey-Tubman KE, Lee YE, Robbiani DF, Nussenzweig MC, West AP, Bjorkman PJ. Nature 588 682-687 (2020)
  8. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Corbett KS, Swanson PA, Padilla M, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Martinez DR, Baric R, Buchanan W, Luke CJ, Phadke VK, Rostad CA, Ledgerwood JE, Graham BS, Beigel JH, mRNA-1273 Study Group. N Engl J Med 383 2427-2438 (2020)
  9. Site-specific glycan analysis of the SARS-CoV-2 spike. Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Science 369 330-333 (2020)
  10. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, Silacci-Fregni C, Pinto D, Rosen LE, Bowen JE, Acton OJ, Jaconi S, Guarino B, Minola A, Zatta F, Sprugasci N, Bassi J, Peter A, De Marco A, Nix JC, Mele F, Jovic S, Rodriguez BF, Gupta SV, Jin F, Piumatti G, Lo Presti G, Pellanda AF, Biggiogero M, Tarkowski M, Pizzuto MS, Cameroni E, Havenar-Daughton C, Smithey M, Hong D, Lepori V, Albanese E, Ceschi A, Bernasconi E, Elzi L, Ferrari P, Garzoni C, Riva A, Snell G, Sallusto F, Fink K, Virgin HW, Lanzavecchia A, Corti D, Veesler D. Cell 183 1024-1042.e21 (2020)
  11. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, Dinnon KH, Elbashir SM, Shaw CA, Woods A, Fritch EJ, Martinez DR, Bock KW, Minai M, Nagata BM, Hutchinson GB, Wu K, Henry C, Bahl K, Garcia-Dominguez D, Ma L, Renzi I, Kong WP, Schmidt SD, Wang L, Zhang Y, Phung E, Chang LA, Loomis RJ, Altaras NE, Narayanan E, Metkar M, Presnyak V, Liu C, Louder MK, Shi W, Leung K, Yang ES, West A, Gully KL, Stevens LJ, Wang N, Wrapp D, Doria-Rose NA, Stewart-Jones G, Bennett H, Alvarado GS, Nason MC, Ruckwardt TJ, McLellan JS, Denison MR, Chappell JD, Moore IN, Morabito KM, Mascola JR, Baric RS, Carfi A, Graham BS. Nature 586 567-571 (2020)
  12. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, Torres JL, Okba NMA, Claireaux M, Kerster G, Bentlage AEH, van Haaren MM, Guerra D, Burger JA, Schermer EE, Verheul KD, van der Velde N, van der Kooi A, van Schooten J, van Breemen MJ, Bijl TPL, Sliepen K, Aartse A, Derking R, Bontjer I, Kootstra NA, Wiersinga WJ, Vidarsson G, Haagmans BL, Ward AB, de Bree GJ, Sanders RW, van Gils MJ. Science 369 643-650 (2020)
  13. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nkolola JP, Liu J, Li Z, Chandrashekar A, Martinez DR, Loos C, Atyeo C, Fischinger S, Burke JS, Slein MD, Chen Y, Zuiani A, Lelis FJN, Travers M, Habibi S, Pessaint L, Van Ry A, Blade K, Brown R, Cook A, Finneyfrock B, Dodson A, Teow E, Velasco J, Zahn R, Wegmann F, Bondzie EA, Dagotto G, Gebre MS, He X, Jacob-Dolan C, Kirilova M, Kordana N, Lin Z, Maxfield LF, Nampanya F, Nityanandam R, Ventura JD, Wan H, Cai Y, Chen B, Schmidt AG, Wesemann DR, Baric RS, Alter G, Andersen H, Lewis MG, Barouch DH. Science 369 806-811 (2020)
  14. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O'Connell S, Bock KW, Minai M, Nagata BM, Andersen H, Martinez DR, Noe AT, Douek N, Donaldson MM, Nji NN, Alvarado GS, Edwards DK, Flebbe DR, Lamb E, Doria-Rose NA, Lin BC, Louder MK, O'Dell S, Schmidt SD, Phung E, Chang LA, Yap C, Todd JM, Pessaint L, Van Ry A, Browne S, Greenhouse J, Putman-Taylor T, Strasbaugh A, Campbell TA, Cook A, Dodson A, Steingrebe K, Shi W, Zhang Y, Abiona OM, Wang L, Pegu A, Yang ES, Leung K, Zhou T, Teng IT, Widge A, Gordon I, Novik L, Gillespie RA, Loomis RJ, Moliva JI, Stewart-Jones G, Himansu S, Kong WP, Nason MC, Morabito KM, Ruckwardt TJ, Ledgerwood JE, Gaudinski MR, Kwong PD, Mascola JR, Carfi A, Lewis MG, Baric RS, McDermott A, Moore IN, Sullivan NJ, Roederer M, Seder RA, Graham BS. N Engl J Med 383 1544-1555 (2020)
  15. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Hsieh CL, Goldsmith JA, Schaub JM, DiVenere AM, Kuo HC, Javanmardi K, Le KC, Wrapp D, Lee AG, Liu Y, Chou CW, Byrne PO, Hjorth CK, Johnson NV, Ludes-Meyers J, Nguyen AW, Park J, Wang N, Amengor D, Lavinder JJ, Ippolito GC, Maynard JA, Finkelstein IJ, McLellan JS. Science 369 1501-1505 (2020)
  16. Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. Yurkovetskiy L, Wang X, Pascal KE, Tomkins-Tinch C, Nyalile TP, Wang Y, Baum A, Diehl WE, Dauphin A, Carbone C, Veinotte K, Egri SB, Schaffner SF, Lemieux JE, Munro JB, Rafique A, Barve A, Sabeti PC, Kyratsous CA, Dudkina NV, Shen K, Luban J. Cell 183 739-751.e8 (2020)
  17. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, Liu J, Peter L, McMahan K, Tostanoski LH, He X, Martinez DR, Rutten L, Bos R, van Manen D, Vellinga J, Custers J, Langedijk JP, Kwaks T, Bakkers MJG, Zuijdgeest D, Rosendahl Huber SK, Atyeo C, Fischinger S, Burke JS, Feldman J, Hauser BM, Caradonna TM, Bondzie EA, Dagotto G, Gebre MS, Hoffman E, Jacob-Dolan C, Kirilova M, Li Z, Lin Z, Mahrokhian SH, Maxfield LF, Nampanya F, Nityanandam R, Nkolola JP, Patel S, Ventura JD, Verrington K, Wan H, Pessaint L, Van Ry A, Blade K, Strasbaugh A, Cabus M, Brown R, Cook A, Zouantchangadou S, Teow E, Andersen H, Lewis MG, Cai Y, Chen B, Schmidt AG, Reeves RK, Baric RS, Lauffenburger DA, Alter G, Stoffels P, Mammen M, Van Hoof J, Schuitemaker H, Barouch DH. Nature 586 583-588 (2020)
  18. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl C, Wrobel AG, Benton DJ, Roustan C, Bolland W, Thompson R, Agua-Doce A, Hobson P, Heaney J, Rickman H, Paraskevopoulou S, Houlihan CF, Thomson K, Sanchez E, Shin GY, Spyer MJ, Joshi D, O'Reilly N, Walker PA, Kjaer S, Riddell A, Moore C, Jebson BR, Wilkinson M, Marshall LR, Rosser EC, Radziszewska A, Peckham H, Ciurtin C, Wedderburn LR, Beale R, Swanton C, Gandhi S, Stockinger B, McCauley J, Gamblin SJ, McCoy LE, Cherepanov P, Nastouli E, Kassiotis G. Science 370 1339-1343 (2020)
  19. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Barnes CO, West AP, Huey-Tubman KE, Hoffmann MAG, Sharaf NG, Hoffman PR, Koranda N, Gristick HB, Gaebler C, Muecksch F, Lorenzi JCC, Finkin S, Hägglöf T, Hurley A, Millard KG, Weisblum Y, Schmidt F, Hatziioannou T, Bieniasz PD, Caskey M, Robbiani DF, Nussenzweig MC, Bjorkman PJ. Cell 182 828-842.e16 (2020)
  20. Molecular Architecture of the SARS-CoV-2 Virus. Yao H, Song Y, Chen Y, Wu N, Xu J, Sun C, Zhang J, Weng T, Zhang Z, Wu Z, Cheng L, Shi D, Lu X, Lei J, Crispin M, Shi Y, Li L, Li S. Cell 183 730-738.e13 (2020)
  21. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, Li Z, Chao G, Rojas OL, Bang YM, Pu A, Christie-Holmes N, Gervais C, Ceccarelli D, Samavarchi-Tehrani P, Guvenc F, Budylowski P, Li A, Paterson A, Yue FY, Marin LM, Caldwell L, Wrana JL, Colwill K, Sicheri F, Mubareka S, Gray-Owen SD, Drews SJ, Siqueira WL, Barrios-Rodiles M, Ostrowski M, Rini JM, Durocher Y, McGeer AJ, Gommerman JL, Gingras AC. Sci Immunol 5 eabe5511 (2020)
  22. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. Song W, Gui M, Wang X, Xiang Y. PLoS Pathog 14 e1007236 (2018)
  23. Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. Casalino L, Gaieb Z, Goldsmith JA, Hjorth CK, Dommer AC, Harbison AM, Fogarty CA, Barros EP, Taylor BC, McLellan JS, Fadda E, Amaro RE. ACS Cent Sci 6 1722-1734 (2020)
  24. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, Lundgreen KA, Reynaldi A, Khoury DS, Pattekar A, Gouma S, Kuri-Cervantes L, Hicks P, Dysinger S, Hicks A, Sharma H, Herring S, Korte S, Baxter AE, Oldridge DA, Giles JR, Weirick ME, McAllister CM, Awofolaju M, Tanenbaum N, Drapeau EM, Dougherty J, Long S, D'Andrea K, Hamilton JT, McLaughlin M, Williams JC, Adamski S, Kuthuru O, UPenn COVID Processing Unit‡, Frank I, Betts MR, Vella LA, Grifoni A, Weiskopf D, Sette A, Hensley SE, Davenport MP, Bates P, Luning Prak ET, Greenplate AR, Wherry EJ. Science 374 abm0829 (2021)
  25. Structural insights into coronavirus entry. Tortorici MA, Veesler D. Adv Virus Res 105 93-116 (2019)
  26. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Benton DJ, Wrobel AG, Xu P, Roustan C, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ. Nature 588 327-330 (2020)
  27. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, Lei T, Thapa M, Chen RE, Case JB, Amanat F, Rauseo AM, Haile A, Xie X, Klebert MK, Suessen T, Middleton WD, Shi PY, Krammer F, Teefey SA, Diamond MS, Presti RM, Ellebedy AH. Nature 596 109-113 (2021)
  28. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Wec AZ, Wrapp D, Herbert AS, Maurer DP, Haslwanter D, Sakharkar M, Jangra RK, Dieterle ME, Lilov A, Huang D, Tse LV, Johnson NV, Hsieh CL, Wang N, Nett JH, Champney E, Burnina I, Brown M, Lin S, Sinclair M, Johnson C, Pudi S, Bortz R, Wirchnianski AS, Laudermilch E, Florez C, Fels JM, O'Brien CM, Graham BS, Nemazee D, Burton DR, Baric RS, Voss JE, Chandran K, Dye JM, McLellan JS, Walker LM. Science 369 731-736 (2020)
  29. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, He L, Chen Y, Wu J, Shi Z, Zhou Y, Du L, Li F. J Virol 94 e02015-19 (2020)
  30. Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. Walls AC, Xiong X, Park YJ, Tortorici MA, Snijder J, Quispe J, Cameroni E, Gopal R, Dai M, Lanzavecchia A, Zambon M, Rey FA, Corti D, Veesler D. Cell 176 1026-1039.e15 (2019)
  31. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Tortorici MA, Beltramello M, Lempp FA, Pinto D, Dang HV, Rosen LE, McCallum M, Bowen J, Minola A, Jaconi S, Zatta F, De Marco A, Guarino B, Bianchi S, Lauron EJ, Tucker H, Zhou J, Peter A, Havenar-Daughton C, Wojcechowskyj JA, Case JB, Chen RE, Kaiser H, Montiel-Ruiz M, Meury M, Czudnochowski N, Spreafico R, Dillen J, Ng C, Sprugasci N, Culap K, Benigni F, Abdelnabi R, Foo SC, Schmid MA, Cameroni E, Riva A, Gabrieli A, Gabrieli A, Galli M, Pizzuto MS, Neyts J, Diamond MS, Virgin HW, Snell G, Corti D, Fink K, Veesler D. Science 370 950-957 (2020)
  32. Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Walls AC, Tortorici MA, Snijder J, Xiong X, Bosch BJ, Rey FA, Veesler D. Proc Natl Acad Sci U S A 114 11157-11162 (2017)
  33. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, Kranz LM, Walzer KC, Hein S, Güler A, Loschko J, Maddur MS, Ota-Setlik A, Tompkins K, Cole J, Lui BG, Ziegenhals T, Plaschke A, Eisel D, Dany SC, Fesser S, Erbar S, Bates F, Schneider D, Jesionek B, Sänger B, Wallisch AK, Feuchter Y, Junginger H, Krumm SA, Heinen AP, Adams-Quack P, Schlereth J, Schille S, Kröner C, de la Caridad Güimil Garcia R, Hiller T, Fischer L, Sellers RS, Choudhary S, Gonzalez O, Vascotto F, Gutman MR, Fontenot JA, Hall-Ursone S, Brasky K, Griffor MC, Han S, Su AAH, Lees JA, Nedoma NL, Mashalidis EH, Sahasrabudhe PV, Tan CY, Pavliakova D, Singh G, Fontes-Garfias C, Pride M, Scully IL, Ciolino T, Obregon J, Gazi M, Carrion R, Alfson KJ, Kalina WV, Kaushal D, Shi PY, Klamp T, Rosenbaum C, Kuhn AN, Türeci Ö, Dormitzer PR, Jansen KU, Sahin U. Nature 592 283-289 (2021)
  34. Structural basis for human coronavirus attachment to sialic acid receptors. Tortorici MA, Walls AC, Lang Y, Wang C, Li Z, Koerhuis D, Boons GJ, Bosch BJ, Rey FA, de Groot RJ, Veesler D. Nat Struct Mol Biol 26 481-489 (2019)
  35. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. Wrobel AG, Benton DJ, Xu P, Roustan C, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ. Nat Struct Mol Biol 27 763-767 (2020)
  36. A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, Chen RE, Winkler ES, Wessel AW, Case JB, Kashentseva E, McCune BT, Bailey AL, Zhao H, VanBlargan LA, Dai YN, Ma M, Adams LJ, Shrihari S, Danis JE, Gralinski LE, Hou YJ, Schäfer A, Kim AS, Keeler SP, Weiskopf D, Baric RS, Holtzman MJ, Fremont DH, Curiel DT, Diamond MS. Cell 183 169-184.e13 (2020)
  37. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Kirchdoerfer RN, Wang N, Pallesen J, Wrapp D, Turner HL, Cottrell CA, Corbett KS, Graham BS, McLellan JS, Ward AB. Sci Rep 8 15701 (2018)
  38. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, Roose K, van Schie L, VIB-CMB COVID-19 Response Team, Hoffmann M, Pöhlmann S, Graham BS, Callewaert N, Schepens B, Saelens X, McLellan JS. Cell 181 1004-1015.e15 (2020)
  39. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cerutti G, Guo Y, Zhou T, Gorman J, Lee M, Rapp M, Reddem ER, Yu J, Bahna F, Bimela J, Huang Y, Katsamba PS, Liu L, Nair MS, Rawi R, Olia AS, Wang P, Zhang B, Chuang GY, Ho DD, Sheng Z, Kwong PD, Shapiro L. Cell Host Microbe 29 819-833.e7 (2021)
  40. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Seydoux E, Homad LJ, MacCamy AJ, Parks KR, Hurlburt NK, Jennewein MF, Akins NR, Stuart AB, Wan YH, Feng J, Whaley RE, Singh S, Boeckh M, Cohen KW, McElrath MJ, Englund JA, Chu HY, Pancera M, McGuire AT, Stamatatos L. Immunity 53 98-105.e5 (2020)
  41. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O'Connor MA, Chen C, Navarro MJ, Miranda MC, Pettie D, Ravichandran R, Kraft JC, Ogohara C, Palser A, Chalk S, Lee EC, Guerriero K, Kepl E, Chow CM, Sydeman C, Hodge EA, Brown B, Fuller JT, Dinnon KH, Gralinski LE, Leist SR, Gully KL, Lewis TB, Guttman M, Chu HY, Lee KK, Fuller DH, Baric RS, Kellam P, Carter L, Pepper M, Sheahan TP, Veesler D, King NP. Cell 183 1367-1382.e17 (2020)
  42. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, An Y, Cheng Y, Li S, Liu M, Yang M, Li Y, Cheng H, Yuan Y, Zhang W, Ke C, Wong G, Qi J, Qin C, Yan J, Gao GF. Cell 182 722-733.e11 (2020)
  43. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, Portnoff AD, Norton J, Guebre-Xabier M, Zhou B, Jacobson K, Maciejewski S, Khatoon R, Wisniewska M, Moffitt W, Kluepfel-Stahl S, Ekechukwu B, Papin J, Boddapati S, Jason Wong C, Piedra PA, Frieman MB, Massare MJ, Fries L, Bengtsson KL, Stertman L, Ellingsworth L, Glenn G, Smith G. Nat Commun 12 372 (2021)
  44. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Lv Z, Deng YQ, Ye Q, Cao L, Sun CY, Fan C, Huang W, Sun S, Sun Y, Zhu L, Chen Q, Wang N, Nie J, Cui Z, Zhu D, Shaw N, Li XF, Li Q, Xie L, Wang Y, Rao Z, Qin CF, Wang X. Science 369 1505-1509 (2020)
  45. Controlling the SARS-CoV-2 spike glycoprotein conformation. Henderson R, Edwards RJ, Mansouri K, Janowska K, Stalls V, Gobeil SMC, Kopp M, Li D, Parks R, Hsu AL, Borgnia MJ, Haynes BF, Acharya P. Nat Struct Mol Biol 27 925-933 (2020)
  46. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Chen X, Li R, Pan Z, Qian C, Yang Y, You R, Zhao J, Liu P, Gao L, Li Z, Huang Q, Xu L, Tang J, Tian Q, Yao W, Hu L, Yan X, Zhou X, Wu Y, Deng K, Zhang Z, Qian Z, Chen Y, Ye L. Cell Mol Immunol 17 647-649 (2020)
  47. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Weissman D, Alameh MG, de Silva T, Collini P, Hornsby H, Brown R, LaBranche CC, Edwards RJ, Sutherland L, Santra S, Mansouri K, Gobeil S, McDanal C, Pardi N, Hengartner N, Lin PJC, Tam Y, Shaw PA, Lewis MG, Boesler C, Şahin U, Acharya P, Haynes BF, Korber B, Montefiori DC. Cell Host Microbe 29 23-31.e4 (2021)
  48. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Yuan M, Huang D, Lee CD, Wu NC, Jackson AM, Zhu X, Liu H, Peng L, van Gils MJ, Sanders RW, Burton DR, Reincke SM, Prüss H, Kreye J, Nemazee D, Ward AB, Wilson IA. Science 373 818-823 (2021)
  49. Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. Xu C, Wang Y, Liu C, Zhang C, Han W, Hong X, Wang Y, Hong Q, Wang S, Zhao Q, Wang Y, Yang Y, Chen K, Zheng W, Kong L, Wang F, Zuo Q, Huang Z, Cong Y. Sci Adv 7 eabe5575 (2021)
  50. Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Grant OC, Montgomery D, Ito K, Woods RJ. Sci Rep 10 14991 (2020)
  51. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. Bos R, Rutten L, van der Lubbe JEM, Bakkers MJG, Hardenberg G, Wegmann F, Zuijdgeest D, de Wilde AH, Koornneef A, Verwilligen A, van Manen D, Kwaks T, Vogels R, Dalebout TJ, Myeni SK, Kikkert M, Snijder EJ, Li Z, Barouch DH, Vellinga J, Langedijk JPM, Zahn RC, Custers J, Schuitemaker H. NPJ Vaccines 5 91 (2020)
  52. Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. Zhou T, Tsybovsky Y, Gorman J, Rapp M, Cerutti G, Chuang GY, Katsamba PS, Sampson JM, Schön A, Bimela J, Boyington JC, Nazzari A, Olia AS, Shi W, Sastry M, Stephens T, Stuckey J, Teng IT, Wang P, Wang S, Zhang B, Friesner RA, Ho DD, Mascola JR, Shapiro L, Kwong PD. Cell Host Microbe 28 867-879.e5 (2020)
  53. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Koenig PA, Das H, Liu H, Kümmerer BM, Gohr FN, Jenster LM, Schiffelers LDJ, Tesfamariam YM, Uchima M, Wuerth JD, Gatterdam K, Ruetalo N, Christensen MH, Fandrey CI, Normann S, Tödtmann JMP, Pritzl S, Hanke L, Boos J, Yuan M, Zhu X, Schmid-Burgk JL, Kato H, Schindler M, Wilson IA, Geyer M, Ludwig KU, Hällberg BM, Wu NC, Schmidt FI. Science 371 eabe6230 (2021)
  54. Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Watanabe Y, Berndsen ZT, Raghwani J, Seabright GE, Allen JD, Pybus OG, McLellan JS, Wilson IA, Bowden TA, Ward AB, Crispin M. Nat Commun 11 2688 (2020)
  55. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Song G, He WT, Callaghan S, Anzanello F, Huang D, Ricketts J, Torres JL, Beutler N, Peng L, Vargas S, Cassell J, Parren M, Yang L, Ignacio C, Smith DM, Voss JE, Nemazee D, Ward AB, Rogers T, Burton DR, Andrabi R. Nat Commun 12 2938 (2021)
  56. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Zhou D, Duyvesteyn HME, Chen CP, Huang CG, Chen TH, Shih SR, Lin YC, Cheng CY, Cheng SH, Huang YC, Lin TY, Ma C, Huo J, Carrique L, Malinauskas T, Ruza RR, Shah PNM, Tan TK, Rijal P, Donat RF, Godwin K, Buttigieg KR, Tree JA, Radecke J, Paterson NG, Supasa P, Mongkolsapaya J, Screaton GR, Carroll MW, Gilbert-Jaramillo J, Knight ML, James W, Owens RJ, Naismith JH, Townsend AR, Fry EE, Zhao Y, Ren J, Stuart DI, Huang KA. Nat Struct Mol Biol 27 950-958 (2020)
  57. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Corbett KS, Nason MC, Flach B, Gagne M, O'Connell S, Johnston TS, Shah SN, Edara VV, Floyd K, Lai L, McDanal C, Francica JR, Flynn B, Wu K, Choi A, Koch M, Abiona OM, Werner AP, Moliva JI, Andrew SF, Donaldson MM, Fintzi J, Flebbe DR, Lamb E, Noe AT, Nurmukhambetova ST, Provost SJ, Cook A, Dodson A, Faudree A, Greenhouse J, Kar S, Pessaint L, Porto M, Steingrebe K, Valentin D, Zouantcha S, Bock KW, Minai M, Nagata BM, van de Wetering R, Boyoglu-Barnum S, Leung K, Shi W, Yang ES, Zhang Y, Todd JM, Wang L, Alvarado GS, Andersen H, Foulds KE, Edwards DK, Mascola JR, Moore IN, Lewis MG, Carfi A, Montefiori D, Suthar MS, McDermott A, Roederer M, Sullivan NJ, Douek DC, Graham BS, Seder RA. Science 373 eabj0299 (2021)
  58. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Huo J, Zhao Y, Ren J, Zhou D, Duyvesteyn HME, Ginn HM, Carrique L, Malinauskas T, Ruza RR, Shah PNM, Tan TK, Rijal P, Coombes N, Bewley KR, Tree JA, Radecke J, Paterson NG, Supasa P, Mongkolsapaya J, Screaton GR, Carroll M, Townsend A, Fry EE, Owens RJ, Stuart DI. Cell Host Microbe 28 445-454.e6 (2020)
  59. D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction. Gobeil SM, Janowska K, McDowell S, Mansouri K, Parks R, Manne K, Stalls V, Kopp MF, Henderson R, Edwards RJ, Haynes BF, Acharya P. Cell Rep 34 108630 (2021)
  60. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Amanat F, Thapa M, Lei T, Ahmed SMS, Adelsberg DC, Carreño JM, Strohmeier S, Schmitz AJ, Zafar S, Zhou JQ, Rijnink W, Alshammary H, Borcherding N, Reiche AG, Srivastava K, Sordillo EM, van Bakel H, Personalized Virology Initiative, Turner JS, Bajic G, Simon V, Ellebedy AH, Krammer F. Cell 184 3936-3948.e10 (2021)
  61. Proinflammatory IgG Fc structures in patients with severe COVID-19. Chakraborty S, Gonzalez J, Edwards K, Mallajosyula V, Buzzanco AS, Sherwood R, Buffone C, Kathale N, Providenza S, Xie MM, Andrews JR, Blish CA, Singh U, Dugan H, Wilson PC, Pham TD, Boyd SD, Nadeau KC, Pinsky BA, Zhang S, Memoli MJ, Taubenberger JK, Morales T, Schapiro JM, Tan GS, Jagannathan P, Wang TT. Nat Immunol 22 67-73 (2021)
  62. A glycan gate controls opening of the SARS-CoV-2 spike protein. Sztain T, Ahn SH, Bogetti AT, Casalino L, Goldsmith JA, Seitz E, McCool RS, Kearns FL, Acosta-Reyes F, Maji S, Mashayekhi G, McCammon JA, Ourmazd A, Frank J, McLellan JS, Chong LT, Amaro RE. Nat Chem 13 963-968 (2021)
  63. A thermostable, closed SARS-CoV-2 spike protein trimer. Xiong X, Qu K, Ciazynska KA, Hosmillo M, Carter AP, Ebrahimi S, Ke Z, Scheres SHW, Bergamaschi L, Grice GL, Zhang Y, CITIID-NIHR COVID-19 BioResource Collaboration, Nathan JA, Baker S, James LC, Baxendale HE, Goodfellow I, Doffinger R, Briggs JAG. Nat Struct Mol Biol 27 934-941 (2020)
  64. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Gagne M, Moliva JI, Foulds KE, Andrew SF, Flynn BJ, Werner AP, Wagner DA, Teng IT, Lin BC, Moore C, Jean-Baptiste N, Carroll R, Foster SL, Patel M, Ellis M, Edara VV, Maldonado NV, Minai M, McCormick L, Honeycutt CC, Nagata BM, Bock KW, Dulan CNM, Cordon J, Flebbe DR, Todd JM, McCarthy E, Pessaint L, Van Ry A, Narvaez B, Valentin D, Cook A, Dodson A, Steingrebe K, Nurmukhambetova ST, Godbole S, Henry AR, Laboune F, Roberts-Torres J, Lorang CG, Amin S, Trost J, Naisan M, Basappa M, Willis J, Wang L, Shi W, Doria-Rose NA, Zhang Y, Yang ES, Leung K, O'Dell S, Schmidt SD, Olia AS, Liu C, Harris DR, Chuang GY, Stewart-Jones G, Renzi I, Lai YT, Malinowski A, Wu K, Mascola JR, Carfi A, Kwong PD, Edwards DK, Lewis MG, Andersen H, Corbett KS, Nason MC, McDermott AB, Suthar MS, Moore IN, Roederer M, Sullivan NJ, Douek DC, Seder RA. Cell 185 1556-1571.e18 (2022)
  65. Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors. Park YJ, Walls AC, Wang Z, Sauer MM, Li W, Tortorici MA, Bosch BJ, DiMaio F, Veesler D. Nat Struct Mol Biol 26 1151-1157 (2019)
  66. News A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. Li Y, Tenchov R, Smoot J, Liu C, Watkins S, Zhou Q. ACS Cent Sci 7 512-533 (2021)
  67. A simple protein-based surrogate neutralization assay for SARS-CoV-2. Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, Budylowski P, Dupuis AP, Girardin RC, Rathod B, Wang JH, Barrios-Rodiles M, Colwill K, McGeer AJ, Mubareka S, Gommerman JL, Durocher Y, Ostrowski M, McDonough KA, Drebot MA, Drews SJ, Rini JM, Gingras AC. JCI Insight 5 142362 (2020)
  68. A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. Alsoussi WB, Turner JS, Case JB, Zhao H, Schmitz AJ, Zhou JQ, Chen RE, Lei T, Rizk AA, McIntire KM, Winkler ES, Fox JM, Kafai NM, Thackray LB, Hassan AO, Amanat F, Krammer F, Watson CT, Kleinstein SH, Fremont DH, Diamond MS, Ellebedy AH. J Immunol 205 915-922 (2020)
  69. Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses. Hicks J, Klumpp-Thomas C, Kalish H, Shunmugavel A, Mehalko J, Denson JP, Snead KR, Drew M, Corbett KS, Graham BS, Hall MD, Memoli MJ, Esposito D, Sadtler K. J Clin Immunol 41 906-913 (2021)
  70. Structural basis for broad coronavirus neutralization. Sauer MM, Tortorici MA, Park YJ, Walls AC, Homad L, Acton OJ, Bowen JE, Wang C, Xiong X, de van der Schueren W, Quispe J, Hoffstrom BG, Bosch BJ, McGuire AT, Veesler D. Nat Struct Mol Biol 28 478-486 (2021)
  71. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. Wang L, Shi W, Chappell JD, Joyce MG, Zhang Y, Kanekiyo M, Becker MM, van Doremalen N, Fischer R, Wang N, Corbett KS, Choe M, Mason RD, Van Galen JG, Zhou T, Saunders KO, Tatti KM, Haynes LM, Kwong PD, Modjarrad K, Kong WP, McLellan JS, Denison MR, Munster VJ, Mascola JR, Graham BS. J Virol 92 e02002-17 (2018)
  72. SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Walls AC, Sprouse KR, Bowen JE, Joshi A, Franko N, Navarro MJ, Stewart C, Cameroni E, McCallum M, Goecker EA, Degli-Angeli EJ, Logue J, Greninger A, Corti D, Chu HY, Veesler D. Cell 185 872-880.e3 (2022)
  73. Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein. Fan X, Cao D, Kong L, Zhang X. Nat Commun 11 3618 (2020)
  74. Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. Menachery VD, Dinnon KH, Yount BL, McAnarney ET, Gralinski LE, Hale A, Graham RL, Scobey T, Anthony SJ, Wang L, Graham B, Randell SH, Lipkin WI, Baric RS. J Virol 94 e01774-19 (2020)
  75. Factors Associated With Intubation and Prolonged Intubation in Hospitalized Patients With COVID-19. Hur K, Price CPE, Gray EL, Gulati RK, Maksimoski M, Racette SD, Schneider AL, Khanwalkar AR. Otolaryngol Head Neck Surg 163 170-178 (2020)
  76. The human coronavirus HCoV-229E S-protein structure and receptor binding. Li Z, Tomlinson AC, Wong AH, Zhou D, Desforges M, Talbot PJ, Benlekbir S, Rubinstein JL, Rini JM. Elife 8 e51230 (2019)
  77. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Walls AC, Miranda MC, Schäfer A, Pham MN, Greaney A, Arunachalam PS, Navarro MJ, Tortorici MA, Rogers K, O'Connor MA, Shirreff L, Ferrell DE, Bowen J, Brunette N, Kepl E, Zepeda SK, Starr T, Hsieh CL, Fiala B, Wrenn S, Pettie D, Sydeman C, Sprouse KR, Johnson M, Blackstone A, Ravichandran R, Ogohara C, Carter L, Tilles SW, Rappuoli R, Leist SR, Martinez DR, Clark M, Tisch R, O'Hagan DT, Van Der Most R, Van Voorhis WC, Corti D, McLellan JS, Kleanthous H, Sheahan TP, Smith KD, Fuller DH, Villinger F, Bloom J, Pulendran B, Baric RS, King NP, Veesler D. Cell 184 5432-5447.e16 (2021)
  78. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Brouwer PJM, Brinkkemper M, Maisonnasse P, Dereuddre-Bosquet N, Grobben M, Claireaux M, de Gast M, Marlin R, Chesnais V, Diry S, Allen JD, Watanabe Y, Giezen JM, Kerster G, Turner HL, van der Straten K, van der Linden CA, Aldon Y, Naninck T, Bontjer I, Burger JA, Poniman M, Mykytyn AZ, Okba NMA, Schermer EE, van Breemen MJ, Ravichandran R, Caniels TG, van Schooten J, Kahlaoui N, Contreras V, Lemaître J, Chapon C, Fang RHT, Villaudy J, Sliepen K, van der Velden YU, Haagmans BL, de Bree GJ, Ginoux E, Ward AB, Crispin M, King NP, van der Werf S, van Gils MJ, Le Grand R, Sanders RW. Cell 184 1188-1200.e19 (2021)
  79. A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. Powell AE, Zhang K, Sanyal M, Tang S, Weidenbacher PA, Li S, Pham TD, Pak JE, Chiu W, Kim PS. ACS Cent Sci 7 183-199 (2021)
  80. DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist. Thépaut M, Luczkowiak J, Vivès C, Labiod N, Bally I, Lasala F, Grimoire Y, Fenel D, Sattin S, Thielens N, Schoehn G, Bernardi A, Delgado R, Fieschi F. PLoS Pathog 17 e1009576 (2021)
  81. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Zhou P, Yuan M, Song G, Beutler N, Shaabani N, Huang D, He WT, Zhu X, Callaghan S, Yong P, Anzanello F, Peng L, Ricketts J, Parren M, Garcia E, Rawlings SA, Smith DM, Nemazee D, Teijaro JR, Rogers TF, Wilson IA, Burton DR, Andrabi R. Sci Transl Med 14 eabi9215 (2022)
  82. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19. Kuo TY, Lin MY, Coffman RL, Campbell JD, Traquina P, Lin YJ, Liu LT, Cheng J, Wu YC, Wu CC, Tang WH, Huang CG, Tsao KC, Chen C. Sci Rep 10 20085 (2020)
  83. Stabilizing the closed SARS-CoV-2 spike trimer. Juraszek J, Rutten L, Blokland S, Bouchier P, Voorzaat R, Ritschel T, Bakkers MJG, Renault LLR, Langedijk JPM. Nat Commun 12 244 (2021)
  84. Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. McCallum M, Walls AC, Bowen JE, Corti D, Veesler D. Nat Struct Mol Biol 27 942-949 (2020)
  85. mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. Rauch S, Roth N, Schwendt K, Fotin-Mleczek M, Mueller SO, Petsch B. NPJ Vaccines 6 57 (2021)
  86. Glycan Shield and Fusion Activation of a Deltacoronavirus Spike Glycoprotein Fine-Tuned for Enteric Infections. Xiong X, Tortorici MA, Snijder J, Yoshioka C, Walls AC, Li W, McGuire AT, Rey FA, Bosch BJ, Veesler D. J Virol 92 e01628-17 (2018)
  87. Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. Watanabe Y, Mendonça L, Allen ER, Howe A, Lee M, Allen JD, Chawla H, Pulido D, Donnellan F, Davies H, Ulaszewska M, Belij-Rammerstorfer S, Morris S, Krebs AS, Dejnirattisai W, Mongkolsapaya J, Supasa P, Screaton GR, Green CM, Lambe T, Zhang P, Gilbert SC, Crispin M. ACS Cent Sci 7 594-602 (2021)
  88. Rational Vaccine Design in the Time of COVID-19. Burton DR, Walker LM. Cell Host Microbe 27 695-698 (2020)
  89. Cryo-EM structure of infectious bronchitis coronavirus spike protein reveals structural and functional evolution of coronavirus spike proteins. Shang J, Zheng Y, Yang Y, Liu C, Geng Q, Luo C, Zhang W, Li F. PLoS Pathog 14 e1007009 (2018)
  90. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Joyce MG, Chen WH, Sankhala RS, Hajduczki A, Thomas PV, Choe M, Martinez EJ, Chang WC, Peterson CE, Morrison EB, Smith C, Chen RE, Ahmed A, Wieczorek L, Anderson A, Case JB, Li Y, Oertel T, Rosado L, Ganesh A, Whalen C, Carmen JM, Mendez-Rivera L, Karch CP, Gohain N, Villar Z, McCurdy D, Beck Z, Kim J, Shrivastava S, Jobe O, Dussupt V, Molnar S, Tran U, Kannadka CB, Soman S, Kuklis C, Zemil M, Khanh H, Wu W, Cole MA, Duso DK, Kummer LW, Lang TJ, Muncil SE, Currier JR, Krebs SJ, Polonis VR, Rajan S, McTamney PM, Esser MT, Reiley WW, Rolland M, de Val N, Diamond MS, Gromowski GD, Matyas GR, Rao M, Michael NL, Modjarrad K. Cell Rep 37 110143 (2021)
  91. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Kremsner PG, Mann P, Kroidl A, Leroux-Roels I, Schindler C, Gabor JJ, Schunk M, Leroux-Roels G, Bosch JJ, Fendel R, Kreidenweiss A, Velavan TP, Fotin-Mleczek M, Mueller SO, Quintini G, Schönborn-Kellenberger O, Vahrenhorst D, Verstraeten T, Alves de Mesquita M, Walz L, Wolz OO, Oostvogels L, CV-NCOV-001 Study Group. Wien Klin Wochenschr 133 931-941 (2021)
  92. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. Goepfert PA, Fu B, Chabanon AL, Bonaparte MI, Davis MG, Essink BJ, Frank I, Haney O, Janosczyk H, Keefer MC, Koutsoukos M, Kimmel MA, Masotti R, Savarino SJ, Schuerman L, Schwartz H, Sher LD, Smith J, Tavares-Da-Silva F, Gurunathan S, DiazGranados CA, de Bruyn G. Lancet Infect Dis 21 1257-1270 (2021)
  93. Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2, the etiologic agent of COVID-19 pandemic: an in silico approach. Rahman MS, Hoque MN, Islam MR, Akter S, Rubayet Ul Alam ASM, Siddique MA, Saha O, Rahaman MM, Sultana M, Crandall KA, Hossain MA. PeerJ 8 e9572 (2020)
  94. Letter Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Eroshenko N, Gill T, Keaveney MK, Church GM, Trevejo JM, Rajaniemi H. Nat Biotechnol 38 789-791 (2020)
  95. Structure and Immune Recognition of the HIV Glycan Shield. Crispin M, Ward AB, Wilson IA. Annu Rev Biophys 47 499-523 (2018)
  96. Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity. Teng S, Sobitan A, Rhoades R, Liu D, Tang Q. Brief Bioinform 22 1239-1253 (2021)
  97. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Jennewein MF, MacCamy AJ, Akins NR, Feng J, Homad LJ, Hurlburt NK, Seydoux E, Wan YH, Stuart AB, Edara VV, Floyd K, Vanderheiden A, Mascola JR, Doria-Rose N, Wang L, Yang ES, Chu HY, Torres JL, Ozorowski G, Ward AB, Whaley RE, Cohen KW, Pancera M, McElrath MJ, Englund JA, Finzi A, Suthar MS, McGuire AT, Stamatatos L. Cell Rep 36 109353 (2021)
  98. Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs. Calligari P, Bobone S, Ricci G, Bocedi A. Viruses 12 E445 (2020)
  99. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Zhang B, Chao CW, Tsybovsky Y, Abiona OM, Hutchinson GB, Moliva JI, Olia AS, Pegu A, Phung E, Stewart-Jones GBE, Verardi R, Wang L, Wang S, Werner A, Yang ES, Yap C, Zhou T, Mascola JR, Sullivan NJ, Graham BS, Corbett KS, Kwong PD. Sci Rep 10 18149 (2020)
  100. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Lambert PH, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, Dekker CL, Didierlaurent AM, Graham BS, Martin SD, Molrine DC, Perlman S, Picard-Fraser PA, Pollard AJ, Qin C, Subbarao K, Cramer JP. Vaccine 38 4783-4791 (2020)
  101. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Ikegame S, Siddiquey MNA, Hung CT, Haas G, Brambilla L, Oguntuyo KY, Kowdle S, Chiu HP, Stevens CS, Vilardo AE, Edelstein A, Perandones C, Kamil JP, Lee B. Nat Commun 12 4598 (2021)
  102. Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. Caniels TG, Bontjer I, van der Straten K, Poniman M, Burger JA, Appelman B, Lavell AHA, Oomen M, Godeke GJ, Valle C, Mögling R, van Willigen HDG, Wynberg E, Schinkel M, van Vught LA, Guerra D, Snitselaar JL, Chaturbhuj DN, Cuella Martin I, Amsterdam UMC COVID-19 S3/HCW study group, Moore JP, de Jong MD, Reusken C, Sikkens JJ, Bomers MK, de Bree GJ, van Gils MJ, Eggink D, Sanders RW. Sci Adv 7 eabj5365 (2021)
  103. A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers. Rutten L, Lai YT, Blokland S, Truan D, Bisschop IJM, Strokappe NM, Koornneef A, van Manen D, Chuang GY, Farney SK, Schuitemaker H, Kwong PD, Langedijk JPM. Cell Rep 23 584-595 (2018)
  104. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. Zhang C, Wang Y, Zhu Y, Liu C, Gu C, Xu S, Wang Y, Zhou Y, Wang Y, Han W, Hong X, Yang Y, Zhang X, Wang T, Xu C, Hong Q, Wang S, Zhao Q, Qiao W, Zang J, Kong L, Wang F, Wang H, Qu D, Lavillette D, Tang H, Deng Q, Xie Y, Cong Y, Huang Z. Nat Commun 12 264 (2021)
  105. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. He L, Lin X, Wang Y, Abraham C, Sou C, Ngo T, Zhang Y, Wilson IA, Zhu J. Sci Adv 7 eabf1591 (2021)
  106. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. Routhu NK, Cheedarla N, Gangadhara S, Bollimpelli VS, Boddapati AK, Shiferaw A, Rahman SA, Sahoo A, Edara VV, Lai L, Floyd K, Wang S, Fischinger S, Atyeo C, Shin SA, Gumber S, Kirejczyk S, Cohen J, Jean SM, Wood JS, Connor-Stroud F, Stammen RL, Upadhyay AA, Pellegrini K, Montefiori D, Shi PY, Menachery VD, Alter G, Vanderford TH, Bosinger SE, Suthar MS, Amara RR. Immunity 54 542-556.e9 (2021)
  107. ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. Low JS, Jerak J, Tortorici MA, McCallum M, Pinto D, Cassotta A, Foglierini M, Mele F, Abdelnabi R, Weynand B, Noack J, Montiel-Ruiz M, Bianchi S, Benigni F, Sprugasci N, Joshi A, Bowen JE, Stewart C, Rexhepaj M, Walls AC, Jarrossay D, Morone D, Paparoditis P, Garzoni C, Ferrari P, Ceschi A, Neyts J, Purcell LA, Snell G, Corti D, Lanzavecchia A, Veesler D, Sallusto F. Science 377 735-742 (2022)
  108. The Challenges of Vaccine Development against a New Virus during a Pandemic. Diamond MS, Pierson TC. Cell Host Microbe 27 699-703 (2020)
  109. Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Guthmiller JJ, Han J, Utset HA, Li L, Lan LY, Henry C, Stamper CT, McMahon M, O'Dell G, Fernández-Quintero ML, Freyn AW, Amanat F, Stovicek O, Gentles L, Richey ST, de la Peña AT, Rosado V, Dugan HL, Zheng NY, Tepora ME, Bitar DJ, Changrob S, Strohmeier S, Huang M, García-Sastre A, Liedl KR, Bloom JD, Nachbagauer R, Palese P, Krammer F, Coughlan L, Ward AB, Wilson PC. Nature 602 314-320 (2022)
  110. Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike. Stalls V, Lindenberger J, Gobeil SM, Henderson R, Parks R, Barr M, Deyton M, Martin M, Janowska K, Huang X, May A, Speakman M, Beaudoin E, Kraft B, Lu X, Edwards RJ, Eaton A, Montefiori DC, Williams WB, Saunders KO, Wiehe K, Haynes BF, Acharya P. Cell Rep 39 111009 (2022)
  111. Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site. Kalathiya U, Padariya M, Mayordomo M, Lisowska M, Nicholson J, Singh A, Baginski M, Fahraeus R, Carragher N, Ball K, Haas J, Daniels A, Hupp TR, Alfaro JA. J Clin Med 9 E1473 (2020)
  112. Assessing Antigen Structural Integrity through Glycosylation Analysis of the SARS-CoV-2 Viral Spike. Brun J, Vasiljevic S, Gangadharan B, Hensen M, V Chandran A, Hill ML, Kiappes JL, Dwek RA, Alonzi DS, Struwe WB, Zitzmann N. ACS Cent Sci 7 586-593 (2021)
  113. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Nabel KG, Clark SA, Shankar S, Pan J, Clark LE, Yang P, Coscia A, McKay LGA, Varnum HH, Brusic V, Tolan NV, Zhou G, Desjardins M, Turbett SE, Kanjilal S, Sherman AC, Dighe A, LaRocque RC, Ryan ET, Tylek C, Cohen-Solal JF, Darcy AT, Tavella D, Clabbers A, Fan Y, Griffiths A, Correia IR, Seagal J, Baden LR, Charles RC, Abraham J. Science 375 eabl6251 (2022)
  114. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection. Liu R, Americo JL, Cotter CA, Earl PL, Erez N, Peng C, Moss B. Proc Natl Acad Sci U S A 118 e2026785118 (2021)
  115. Stabilized coronavirus spike stem elicits a broadly protective antibody. Hsieh CL, Werner AP, Leist SR, Stevens LJ, Falconer E, Goldsmith JA, Chou CW, Abiona OM, West A, Westendorf K, Muthuraman K, Fritch EJ, Dinnon KH, Schäfer A, Denison MR, Chappell JD, Baric RS, Graham BS, Corbett KS, McLellan JS. Cell Rep 37 109929 (2021)
  116. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Zhou T, Teng IT, Olia AS, Cerutti G, Gorman J, Nazzari A, Shi W, Tsybovsky Y, Wang L, Wang S, Zhang B, Zhang Y, Katsamba PS, Petrova Y, Banach BB, Fahad AS, Liu L, Lopez Acevedo SN, Madan B, Oliveira de Souza M, Pan X, Wang P, Wolfe JR, Yin M, Ho DD, Phung E, DiPiazza A, Chang LA, Abiona OM, Corbett KS, DeKosky BJ, Graham BS, Mascola JR, Misasi J, Ruckwardt T, Sullivan NJ, Shapiro L, Kwong PD. Cell Rep 33 108322 (2020)
  117. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Shiakolas AR, Kramer KJ, Wrapp D, Richardson SI, Schäfer A, Wall S, Wang N, Janowska K, Pilewski KA, Venkat R, Parks R, Manamela NP, Raju N, Fechter EF, Holt CM, Suryadevara N, Chen RE, Martinez DR, Nargi RS, Sutton RE, Ledgerwood JE, Graham BS, Diamond MS, Haynes BF, Acharya P, Carnahan RH, Crowe JE, Baric RS, Morris L, McLellan JS, Georgiev IS. Cell Rep Med 2 100313 (2021)
  118. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. Kalnin KV, Plitnik T, Kishko M, Zhang J, Zhang D, Beauvais A, Anosova NG, Tibbitts T, DiNapoli J, Ulinski G, Piepenhagen P, Cummings SM, Bangari DS, Ryan S, Huang PD, Huleatt J, Vincent D, Fries K, Karve S, Goldman R, Gopani H, Dias A, Tran K, Zacharia M, Gu X, Boeglin L, Abysalh J, Vargas J, Beaulieu A, Shah M, Jeannotte T, Gillis K, Chivukula S, Swearingen R, Landolfi V, Fu TM, DeRosa F, Casimiro D. NPJ Vaccines 6 61 (2021)
  119. Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model. Amanat F, Strohmeier S, Rathnasinghe R, Schotsaert M, Coughlan L, García-Sastre A, Krammer F. mBio 12 e02648-20 (2021)
  120. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Pino M, Abid T, Pereira Ribeiro S, Edara VV, Floyd K, Smith JC, Latif MB, Pacheco-Sanchez G, Dutta D, Wang S, Gumber S, Kirejczyk S, Cohen J, Stammen RL, Jean SM, Wood JS, Connor-Stroud F, Pollet J, Chen WH, Wei J, Zhan B, Lee J, Liu Z, Strych U, Shenvi N, Easley K, Weiskopf D, Sette A, Pollara J, Mielke D, Gao H, Eisel N, LaBranche CC, Shen X, Ferrari G, Tomaras GD, Montefiori DC, Sekaly RP, Vanderford TH, Tomai MA, Fox CB, Suthar MS, Kozlowski PA, Hotez PJ, Paiardini M, Bottazzi ME, Kasturi SP. Sci Immunol 6 eabh3634 (2021)
  121. Discovery and Characterization of Spike N-Terminal Domain-Binding Aptamers for Rapid SARS-CoV-2 Detection. Kacherovsky N, Yang LF, Dang HV, Cheng EL, Cardle II, Walls AC, McCallum M, Sellers DL, DiMaio F, Salipante SJ, Corti D, Veesler D, Pun SH. Angew Chem Int Ed Engl 60 21211-21215 (2021)
  122. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Gebre MS, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado NB, He X, Liu J, McMahan K, Martinot A, Martinez DR, Giffin V, Hope D, Patel S, Sellers D, Sanborn O, Barrett J, Liu X, Cole AC, Pessaint L, Valentin D, Flinchbaugh Z, Yalley-Ogunro J, Muench J, Brown R, Cook A, Teow E, Andersen H, Lewis MG, Boon ACM, Baric RS, Mueller SO, Petsch B, Barouch DH. Nature 601 410-414 (2022)
  123. Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating Covid-19 outbreaks. Fantini J, Yahi N, Azzaz F, Chahinian H. J Infect 83 197-206 (2021)
  124. Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus. Kim MH, Kim HJ, Chang J. PLoS One 14 e0220196 (2019)
  125. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. DiPiazza AT, Leist SR, Abiona OM, Moliva JI, Werner A, Minai M, Nagata BM, Bock KW, Phung E, Schäfer A, Dinnon KH, Chang LA, Loomis RJ, Boyoglu-Barnum S, Alvarado GS, Sullivan NJ, Edwards DK, Morabito KM, Mascola JR, Carfi A, Corbett KS, Moore IN, Baric RS, Graham BS, Ruckwardt TJ. Immunity 54 1869-1882.e6 (2021)
  126. CoV3D: a database of high resolution coronavirus protein structures. Gowthaman R, Guest JD, Yin R, Adolf-Bryfogle J, Schief WR, Pierce BG. Nucleic Acids Res 49 D282-D287 (2021)
  127. Development of vaccines and antivirals for combating viral pandemics. Pardi N, Weissman D. Nat Biomed Eng 4 1128-1133 (2020)
  128. Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein. Zhang S, Zhou P, Wang P, Li Y, Jiang L, Jia W, Wang H, Fan A, Wang D, Shi X, Fang X, Hammel M, Wang S, Wang X, Zhang L. Cell Rep 24 441-452 (2018)
  129. Structure and binding properties of Pangolin-CoV spike glycoprotein inform the evolution of SARS-CoV-2. Wrobel AG, Benton DJ, Xu P, Calder LJ, Borg A, Roustan C, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ. Nat Commun 12 837 (2021)
  130. Global site-specific analysis of glycoprotein N-glycan processing. Cao L, Diedrich JK, Ma Y, Wang N, Pauthner M, Park SR, Delahunty CM, McLellan JS, Burton DR, Yates JR, Paulson JC. Nat Protoc 13 1196-1212 (2018)
  131. Immunoinformatics characterization of SARS-CoV-2 spike glycoprotein for prioritization of epitope based multivalent peptide vaccine. Ismail S, Ahmad S, Azam SS. J Mol Liq 314 113612 (2020)
  132. Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation. Allen JD, Chawla H, Samsudin F, Zuzic L, Shivgan AT, Watanabe Y, He WT, Callaghan S, Song G, Yong P, Brouwer PJM, Song Y, Cai Y, Duyvesteyn HME, Malinauskas T, Kint J, Pino P, Wurm MJ, Frank M, Chen B, Stuart DI, Sanders RW, Andrabi R, Burton DR, Li S, Bond PJ, Crispin M. Biochemistry 60 2153-2169 (2021)
  133. The 3.1-Angstrom Cryo-electron Microscopy Structure of the Porcine Epidemic Diarrhea Virus Spike Protein in the Prefusion Conformation. Wrapp D, McLellan JS. J Virol 93 e00923-19 (2019)
  134. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Corbett KS, Werner AP, Connell SO, Gagne M, Lai L, Moliva JI, Flynn B, Choi A, Koch M, Foulds KE, Andrew SF, Flebbe DR, Lamb E, Nurmukhambetova ST, Provost SJ, Bock KW, Minai M, Nagata BM, Ry AV, Flinchbaugh Z, Johnston TS, Mokhtari EB, Mudvari P, Henry AR, Laboune F, Chang B, Porto M, Wear J, Alvarado GS, Boyoglu-Barnum S, Todd JM, Bart B, Cook A, Dodson A, Pessaint L, Steingrebe K, Elbashir S, Sriparna M, Pekosz A, Andersen H, Wu K, Edwards DK, Kar S, Lewis MG, Boritz E, Moore IN, Carfi A, Suthar MS, McDermott A, Roederer M, Nason MC, Sullivan NJ, Douek DC, Graham BS, Seder RA. Nat Immunol 22 1306-1315 (2021)
  135. Fine-tuning the spike: role of the nature and topology of the glycan shield in the structure and dynamics of the SARS-CoV-2 S. Harbison AM, Fogarty CA, Phung TK, Satheesan A, Schulz BL, Fadda E. Chem Sci 13 386-395 (2022)
  136. Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. Hunt AC, Case JB, Park YJ, Cao L, Wu K, Walls AC, Liu Z, Bowen JE, Yeh HW, Saini S, Helms L, Zhao YT, Hsiang TY, Starr TN, Goreshnik I, Kozodoy L, Carter L, Ravichandran R, Green LB, Matochko WL, Thomson CA, Vögeli B, Krüger A, VanBlargan LA, Chen RE, Ying B, Bailey AL, Kafai NM, Boyken SE, Ljubetič A, Edman N, Ueda G, Chow CM, Johnson M, Addetia A, Navarro MJ, Panpradist N, Gale M, Freedman BS, Bloom JD, Ruohola-Baker H, Whelan SPJ, Stewart L, Diamond MS, Veesler D, Jewett MC, Baker D. Sci Transl Med 14 eabn1252 (2022)
  137. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. Li T, Zheng Q, Yu H, Wu D, Xue W, Xiong H, Huang X, Nie M, Yue M, Rong R, Zhang S, Zhang Y, Wu Y, Wang S, Zha Z, Chen T, Deng T, Wang Y, Zhang T, Chen Y, Yuan Q, Zhao Q, Zhang J, Gu Y, Li S, Xia N. Emerg Microbes Infect 9 2076-2090 (2020)
  138. SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. Bowen JE, Park YJ, Stewart C, Brown JT, Sharkey WK, Walls AC, Joshi A, Sprouse KR, McCallum M, Tortorici MA, Franko NM, Logue JK, Mazzitelli IG, Nguyen AW, Silva RP, Huang Y, Low JS, Jerak J, Tiles SW, Ahmed K, Shariq A, Dan JM, Zhang Z, Weiskopf D, Sette A, Snell G, Posavad CM, Iqbal NT, Geffner J, Bandera A, Gori A, Sallusto F, Maynard JA, Crotty S, Van Voorhis WC, Simmerling C, Grifantini R, Chu HY, Corti D, Veesler D. Sci Immunol 7 eadf1421 (2022)
  139. Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. Hsieh SM, Liu WD, Huang YS, Lin YJ, Hsieh EF, Lian WC, Chen C, Janssen R, Shih SR, Huang CG, Tai IC, Chang SC. EClinicalMedicine 38 100989 (2021)
  140. The Sialoside-Binding Pocket of SARS-CoV-2 Spike Glycoprotein Structurally Resembles MERS-CoV. Awasthi M, Gulati S, Sarkar DP, Tiwari S, Kateriya S, Ranjan P, Verma SK. Viruses 12 E909 (2020)
  141. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Francica JR, Flynn BJ, Foulds KE, Noe AT, Werner AP, Moore IN, Gagne M, Johnston TS, Tucker C, Davis RL, Flach B, O'Connell S, Andrew SF, Lamb E, Flebbe DR, Nurmukhambetova ST, Donaldson MM, Todd JM, Zhu AL, Atyeo C, Fischinger S, Gorman MJ, Shin S, Edara VV, Floyd K, Lai L, Boyoglu-Barnum S, Van De Wetering R, Tylor A, McCarthy E, Lecouturier V, Ruiz S, Berry C, Tibbitts T, Andersen H, Cook A, Dodson A, Pessaint L, Van Ry A, Koutsoukos M, Gutzeit C, Teng IT, Zhou T, Li D, Haynes BF, Kwong PD, McDermott A, Lewis MG, Fu TM, Chicz R, van der Most R, Corbett KS, Suthar MS, Alter G, Roederer M, Sullivan NJ, Douek DC, Graham BS, Casimiro D, Seder RA. Sci Transl Med 13 eabi4547 (2021)
  142. Vaccinology in the post-COVID-19 era. Rappuoli R, De Gregorio E, Del Giudice G, Phogat S, Pecetta S, Pizza M, Hanon E. Proc Natl Acad Sci U S A 118 e2020368118 (2021)
  143. The Hantavirus Surface Glycoprotein Lattice and Its Fusion Control Mechanism. Serris A, Stass R, Bignon EA, Muena NA, Manuguerra JC, Jangra RK, Li S, Chandran K, Tischler ND, Huiskonen JT, Rey FA, Guardado-Calvo P. Cell 183 442-456.e16 (2020)
  144. Ca2+-dependent mechanism of membrane insertion and destabilization by the SARS-CoV-2 fusion peptide. Khelashvili G, Plante A, Doktorova M, Weinstein H. Biophys J 120 1105-1119 (2021)
  145. Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters. Jia Q, Bielefeldt-Ohmann H, Maison RM, Masleša-Galić S, Cooper SK, Bowen RA, Horwitz MA. NPJ Vaccines 6 47 (2021)
  146. Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers. Rutten L, Gilman MSA, Blokland S, Juraszek J, McLellan JS, Langedijk JPM. Cell Rep 30 4540-4550.e3 (2020)
  147. Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit. Hurlburt NK, Homad LJ, Sinha I, Jennewein MF, MacCamy AJ, Wan YH, Boonyaratanakornkit J, Sholukh AM, Jackson AM, Zhou P, Burton DR, Andrabi R, Ozorowski G, Ward AB, Stamatatos L, Pancera M, McGuire AT. Commun Biol 5 342 (2022)
  148. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters. Liu X, Luongo C, Matsuoka Y, Park HS, Santos C, Yang L, Moore IN, Afroz S, Johnson RF, Lafont BAP, Martens C, Best SM, Munster VJ, Hollý J, Yewdell JW, Le Nouën C, Munir S, Buchholz UJ. Proc Natl Acad Sci U S A 118 e2109744118 (2021)
  149. Close relatives of MERS-CoV in bats use ACE2 as their functional receptors. Xiong Q, Cao L, Ma C, Tortorici MA, Liu C, Si J, Liu P, Gu M, Walls AC, Wang C, Shi L, Tong F, Huang M, Li J, Zhao C, Shen C, Chen Y, Zhao H, Lan K, Corti D, Veesler D, Wang X, Yan H. Nature 612 748-757 (2022)
  150. The global population of SARS-CoV-2 is composed of six major subtypes. Morais IJ, Polveiro RC, Souza GM, Bortolin DI, Sassaki FT, Lima ATM. Sci Rep 10 18289 (2020)
  151. other Whither COVID-19 vaccines? DeFrancesco L. Nat Biotechnol 38 1132-1145 (2020)
  152. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo. Hanke L, Das H, Sheward DJ, Perez Vidakovics L, Urgard E, Moliner-Morro A, Kim C, Karl V, Pankow A, Smith NL, Porebski B, Fernandez-Capetillo O, Sezgin E, Pedersen GK, Coquet JM, Hällberg BM, Murrell B, McInerney GM. Nat Commun 13 155 (2022)
  153. Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein. Goo J, Jeong Y, Park YS, Yang E, Jung DI, Rho S, Park U, Sung H, Park PG, Choi JA, Seo SH, Cho NH, Lee H, Lee JM, Kim JO, Song M. Virus Res 278 197863 (2020)
  154. Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets. Kim YI, Kim D, Yu KM, Seo HD, Lee SA, Casel MAB, Jang SG, Kim S, Jung W, Lai CJ, Choi YK, Jung JU. mBio 12 e00230-21 (2021)
  155. Evolution of the SARS-CoV-2 spike protein in the human host. Wrobel AG, Benton DJ, Roustan C, Borg A, Hussain S, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ. Nat Commun 13 1178 (2022)
  156. Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19. Capone S, Raggioli A, Gentile M, Battella S, Lahm A, Sommella A, Contino AM, Urbanowicz RA, Scala R, Barra F, Leuzzi A, Lilli E, Miselli G, Noto A, Ferraiuolo M, Talotta F, Tsoleridis T, Castilletti C, Matusali G, Colavita F, Lapa D, Meschi S, Capobianchi M, Soriani M, Folgori A, Ball JK, Colloca S, Vitelli A. Mol Ther 29 2412-2423 (2021)
  157. New Vaccine Design and Delivery Technologies. Kanekiyo M, Ellis D, King NP. J Infect Dis 219 S88-S96 (2019)
  158. N-Glycosylation of the SARS-CoV-2 Receptor Binding Domain Is Important for Functional Expression in Plants. Shin YJ, König-Beihammer J, Vavra U, Schwestka J, Kienzl NF, Klausberger M, Laurent E, Grünwald-Gruber C, Vierlinger K, Hofner M, Margolin E, Weinhäusel A, Stöger E, Mach L, Strasser R. Front Plant Sci 12 689104 (2021)
  159. SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses. Mandolesi M, Sheward DJ, Hanke L, Ma J, Pushparaj P, Perez Vidakovics L, Kim C, Àdori M, Lenart K, Loré K, Castro Dopico X, Coquet JM, McInerney GM, Karlsson Hedestam GB, Murrell B. Cell Rep Med 2 100252 (2021)
  160. Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar. Al Kahlout RA, Nasrallah GK, Farag EA, Wang L, Lattwein E, Müller MA, El Zowalaty ME, Al Romaihi HE, Graham BS, Al Thani AA, Yassine HM. J Immunol Res 2019 1386740 (2019)
  161. Cryo-EM structures of HKU2 and SADS-CoV spike glycoproteins provide insights into coronavirus evolution. Yu J, Qiao S, Guo R, Wang X. Nat Commun 11 3070 (2020)
  162. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates. Pillet S, Arunachalam PS, Andreani G, Golden N, Fontenot J, Aye PP, Röltgen K, Lehmicke G, Gobeil P, Dubé C, Trépanier S, Charland N, D'Aoust MA, Russell-Lodrigue K, Monjure C, Blair RV, Boyd SD, Bohm RP, Rappaport J, Villinger F, Landry N, Pulendran B, Ward BJ. Cell Mol Immunol 19 222-233 (2022)
  163. The prefusion structure of herpes simplex virus glycoprotein B. Vollmer B, Pražák V, Vasishtan D, Jefferys EE, Hernandez-Duran A, Vallbracht M, Klupp BG, Mettenleiter TC, Backovic M, Rey FA, Topf M, Grünewald K. Sci Adv 6 eabc1726 (2020)
  164. Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein. Wrobel AG, Benton DJ, Hussain S, Harvey R, Martin SR, Roustan C, Rosenthal PB, Skehel JJ, Gamblin SJ. Nat Commun 11 5337 (2020)
  165. CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice. Veit S, Jany S, Fux R, Sutter G, Volz A. Viruses 10 E718 (2018)
  166. Free Energy Landscapes from SARS-CoV-2 Spike Glycoprotein Simulations Suggest that RBD Opening Can Be Modulated via Interactions in an Allosteric Pocket. Fallon L, Belfon KAA, Raguette L, Wang Y, Stepanenko D, Cuomo A, Guerra J, Budhan S, Varghese S, Corbo CP, Rizzo RC, Simmerling C. J Am Chem Soc 143 11349-11360 (2021)
  167. Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. Watterson D, Wijesundara DK, Modhiran N, Mordant FL, Li Z, Avumegah MS, McMillan CL, Lackenby J, Guilfoyle K, van Amerongen G, Stittelaar K, Cheung ST, Bibby S, Daleris M, Hoger K, Gillard M, Radunz E, Jones ML, Hughes K, Hughes B, Goh J, Edwards D, Scoble J, Pearce L, Kowalczyk L, Phan T, La M, Lu L, Pham T, Zhou Q, Brockman DA, Morgan SJ, Lau C, Tran MH, Tapley P, Villalón-Letelier F, Barnes J, Young A, Jaberolansar N, Scott CA, Isaacs A, Amarilla AA, Khromykh AA, van den Brand JM, Reading PC, Ranasinghe C, Subbarao K, Munro TP, Young PR, Chappell KJ. Clin Transl Immunology 10 e1269 (2021)
  168. Rapid characterization of spike variants via mammalian cell surface display. Javanmardi K, Chou CW, Terrace CI, Annapareddy A, Kaoud TS, Guo Q, Lutgens J, Zorkic H, Horton AP, Gardner EC, Nguyen G, Boutz DR, Goike J, Voss WN, Kuo HC, Dalby KN, Gollihar JD, Finkelstein IJ. Mol Cell 81 5099-5111.e8 (2021)
  169. Structure and immune recognition of the porcine epidemic diarrhea virus spike protein. Kirchdoerfer RN, Bhandari M, Martini O, Sewall LM, Bangaru S, Yoon KJ, Ward AB. Structure 29 385-392.e5 (2021)
  170. Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. Loomis RJ, Stewart-Jones GBE, Tsybovsky Y, Caringal RT, Morabito KM, McLellan JS, Chamberlain AL, Nugent ST, Hutchinson GB, Kueltzo LA, Mascola JR, Graham BS. Front Immunol 11 842 (2020)
  171. Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike. Díaz-Salinas MA, Li Q, Ejemel M, Yurkovetskiy L, Luban J, Shen K, Wang Y, Munro JB. Elife 11 e75433 (2022)
  172. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. Wørzner K, Sheward DJ, Schmidt ST, Hanke L, Zimmermann J, McInerney G, Karlsson Hedestam GB, Murrell B, Christensen D, Pedersen GK. EBioMedicine 63 103197 (2021)
  173. The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. Andrabi R, Pallesen J, Allen JD, Song G, Zhang J, de Val N, Gegg G, Porter K, Su CY, Pauthner M, Newman A, Bouton-Verville H, Garces F, Wilson IA, Crispin M, Hahn BH, Haynes BF, Verkoczy L, Ward AB, Burton DR. Cell Rep 27 2426-2441.e6 (2019)
  174. Letter Profiles of current COVID-19 vaccines. Heinz FX, Stiasny K. Wien Klin Wochenschr 133 271-283 (2021)
  175. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. Vanshylla K, Fan C, Wunsch M, Poopalasingam N, Meijers M, Kreer C, Kleipass F, Ruchnewitz D, Ercanoglu MS, Gruell H, Münn F, Pohl K, Janicki H, Nolden T, Bartl S, Stein SC, Augustin M, Dewald F, Gieselmann L, Schommers P, Schulz TF, Sander LE, Koch M, Łuksza M, Lässig M, Bjorkman PJ, Klein F. Cell Host Microbe 30 69-82.e10 (2022)
  176. Genomic diversity and evolution, diagnosis, prevention, and therapeutics of the pandemic COVID-19 disease. Hoque MN, Chaudhury A, Akanda MAM, Hossain MA, Islam MT. PeerJ 8 e9689 (2020)
  177. Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses. Silva RP, Huang Y, Nguyen AW, Hsieh CL, Olaluwoye OS, Kaoud TS, Wilen RE, Qerqez AN, Park JG, Khalil AM, Azouz LR, Le KC, Bohanon AL, DiVenere AM, Liu Y, Lee AG, Amengor DA, Shoemaker SR, Costello SM, Padlan EA, Marqusee S, Martinez-Sobrido L, Dalby KN, D'Arcy S, McLellan JS, Maynard JA. Elife 12 e83710 (2023)
  178. Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA. Smith BK, Janowski AB, Danis JE, Harvey IB, Zhao H, Dai YN, Farnsworth CW, Gronowski AM, Roper S, Fremont DH, Wang D. mSphere 6 e01207-20 (2021)
  179. Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. Miersch S, Li Z, Saberianfar R, Ustav M, Brett Case J, Blazer L, Chen C, Ye W, Pavlenco A, Gorelik M, Garcia Perez J, Subramania S, Singh S, Ploder L, Ganaie S, Chen RE, Leung DW, Pandolfi PP, Novelli G, Matusali G, Colavita F, Capobianchi MR, Jain S, Gupta JB, Amarasinghe GK, Diamond MS, Rini J, Sidhu SS. J Mol Biol 433 167177 (2021)
  180. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants. van Oosten L, Altenburg JJ, Fougeroux C, Geertsema C, van den End F, Evers WAC, Westphal AH, Lindhoud S, van den Berg W, Swarts DC, Deurhof L, Suhrbier A, Le TT, Torres Morales S, Myeni SK, Kikkert M, Sander AF, de Jongh WA, Dagil R, Nielsen MA, Salanti A, Søgaard M, Keijzer TMP, Weijers D, Eppink MHM, Wijffels RH, van Oers MM, Martens DE, Pijlman GP. mBio 12 e0181321 (2021)
  181. An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. Liu Z, Xu W, Chen Z, Fu W, Zhan W, Gao Y, Zhou J, Zhou Y, Wu J, Wang Q, Zhang X, Hao A, Wu W, Zhang Q, Li Y, Fan K, Chen R, Jiang Q, Mayer CT, Schoofs T, Xie Y, Jiang S, Wen Y, Yuan Z, Wang K, Lu L, Sun L, Wang Q. Protein Cell 13 655-675 (2022)
  182. Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine. Ferrari D, Clementi N, Criscuolo E, Ambrosi A, Corea F, Di Resta C, Tomaiuolo R, Mancini N, Locatelli M, Plebani M, Banfi G. Vaccines (Basel) 9 1357 (2021)
  183. Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance. Walter JD, Scherer M, Hutter CAJ, Garaeva AA, Zimmermann I, Wyss M, Rheinberger J, Ruedin Y, Earp JC, Egloff P, Sorgenfrei M, Hürlimann LM, Gonda I, Meier G, Remm S, Thavarasah S, van Geest G, Bruggmann R, Zimmer G, Slotboom DJ, Paulino C, Plattet P, Seeger MA. EMBO Rep 23 e54199 (2022)
  184. Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein Through Structure-Guided Design. Riley TP, Chou HT, Hu R, Bzymek KP, Correia AR, Partin AC, Li D, Gong D, Wang Z, Yu X, Manzanillo P, Garces F. Front Immunol 12 660198 (2021)
  185. Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. Nel AE, Miller JF. ACS Nano 15 5793-5818 (2021)
  186. Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design. Ellis D, Brunette N, Crawford KHD, Walls AC, Pham MN, Chen C, Herpoldt KL, Fiala B, Murphy M, Pettie D, Kraft JC, Malone KD, Navarro MJ, Ogohara C, Kepl E, Ravichandran R, Sydeman C, Ahlrichs M, Johnson M, Blackstone A, Carter L, Starr TN, Greaney AJ, Lee KK, Veesler D, Bloom JD, King NP. Front Immunol 12 710263 (2021)
  187. Structural mapping of antibody landscapes to human betacoronavirus spike proteins. Bangaru S, Antanasijevic A, Kose N, Sewall LM, Jackson AM, Suryadevara N, Zhan X, Torres JL, Copps J, de la Peña AT, Crowe JE, Ward AB. Sci Adv 8 eabn2911 (2022)
  188. Alternative conformations of a major antigenic site on RSV F. Jones HG, Battles MB, Lin CC, Bianchi S, Corti D, McLellan JS. PLoS Pathog 15 e1007944 (2019)
  189. Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection. Yilmaz IC, Ipekoglu EM, Bulbul A, Turay N, Yildirim M, Evcili I, Yilmaz NS, Guvencli N, Aydin Y, Gungor B, Saraydar B, Bartan AG, Ibibik B, Bildik T, Baydemir İ, Sanli HA, Kayaoglu B, Ceylan Y, Yildirim T, Abras I, Ayanoglu IC, Cam SB, Ciftci Dede E, Gizer M, Erganis O, Sarac F, Uzar S, Enul H, Adiay C, Aykut G, Polat H, Yildirim IS, Tekin S, Korukluoglu G, Zeytin HE, Korkusuz P, Gursel I, Gursel M. Allergy 77 258-270 (2022)
  190. Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. Bassi J, Giannini O, Silacci-Fregni C, Pertusini L, Hitz P, Terrot T, Franzosi Y, Muoio F, Saliba C, Meury M, Dellota EA, Dillen JR, Hernandez P, Czudnochowski N, Cameroni E, Beria N, Ventresca M, Badellino A, Lavorato-Hadjeres S, Lecchi E, Bonora T, Mattiolo M, Trinci G, Garzoni D, Bonforte G, Forni-Ogna V, Giunzioni D, Berwert L, Gupta RK, Ferrari P, Ceschi A, Cippà P, Corti D, Lanzavecchia A, Piccoli L. PLoS One 17 e0263328 (2022)
  191. Systematic Examination of Antigen-Specific Recall T Cell Responses to SARS-CoV-2 versus Influenza Virus Reveals a Distinct Inflammatory Profile. Law JC, Koh WH, Budylowski P, Lin J, Yue F, Abe KT, Rathod B, Girard M, Li Z, Rini JM, Mubareka S, McGeer A, Chan AK, Gingras AC, Watts TH, Ostrowski MA. J Immunol 206 37-50 (2021)
  192. In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19. Br B, Damle H, Ganju S, Damle L. F1000Res 9 663 (2020)
  193. An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity. Fluckiger AC, Ontsouka B, Bozic J, Diress A, Ahmed T, Berthoud T, Tran A, Duque D, Liao M, McCluskie M, Diaz-Mitoma F, Anderson DE, Soare C. Vaccine 39 4988-5001 (2021)
  194. Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response. Dickey TH, Tang WK, Butler B, Ouahes T, Orr-Gonzalez S, Salinas ND, Lambert LE, Tolia NH. Sci Adv 8 eabq8276 (2022)
  195. Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants. Liu H, Zhou C, An J, Song Y, Yu P, Li J, Gu C, Hu D, Jiang Y, Zhang L, Huang C, Zhang C, Yang Y, Zhu Q, Wang D, Liu Y, Miao C, Cao X, Ding L, Zhu Y, Zhu H, Bao L, Zhou L, Yan H, Fan J, Xu J, Hu Z, Xie Y, Liu J, Liu G. Vaccine 39 7001-7011 (2021)
  196. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. Yang Y, Shi W, Abiona OM, Nazzari A, Olia AS, Ou L, Phung E, Stephens T, Tsybovsky Y, Verardi R, Wang S, Werner A, Yap C, Ambrozak D, Bylund T, Liu T, Nguyen R, Wang L, Zhang B, Zhou T, Chuang GY, Graham BS, Mascola JR, Corbett KS, Kwong PD. Vaccines (Basel) 9 73 (2021)
  197. ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions. Rawle DJ, Le TT, Dumenil T, Yan K, Tang B, Nguyen W, Watterson D, Modhiran N, Hobson-Peters J, Bishop C, Suhrbier A. PLoS Pathog 17 e1009723 (2021)
  198. Biochemical Analysis of Coronavirus Spike Glycoprotein Conformational Intermediates during Membrane Fusion. Kawase M, Kataoka M, Shirato K, Matsuyama S. J Virol 93 e00785-19 (2019)
  199. Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection. Rappaport AR, Hong SJ, Scallan CD, Gitlin L, Akoopie A, Boucher GR, Egorova M, Espinosa JA, Fidanza M, Kachura MA, Shen A, Sivko G, Van Abbema A, Veres RL, Jooss K. Nat Commun 13 3289 (2022)
  200. Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein. Tortorici MA, Walls AC, Joshi A, Park YJ, Eguia RT, Miranda MC, Kepl E, Dosey A, Stevens-Ayers T, Boeckh MJ, Telenti A, Lanzavecchia A, King NP, Corti D, Bloom JD, Veesler D. Cell 185 2279-2291.e17 (2022)
  201. Conformational flexibility and structural variability of SARS-CoV2 S protein. Pramanick I, Sengupta N, Mishra S, Pandey S, Girish N, Das A, Dutta S. Structure 29 834-845.e5 (2021)
  202. Development of a Colloidal Gold-Based Immunochromatographic Strip for Rapid Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein. Li G, Wang A, Chen Y, Sun Y, Du Y, Wang X, Ding P, Jia R, Wang Y, Zhang G. Front Immunol 12 635677 (2021)
  203. Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2. Zhu L, Deng YQ, Zhang RR, Cui Z, Sun CY, Fan CF, Xing X, Huang W, Chen Q, Zhang NN, Ye Q, Cao TS, Wang N, Wang L, Cao L, Wang H, Kong D, Ma J, Luo C, Zhang Y, Nie J, Sun Y, Lv Z, Shaw N, Li Q, Li XF, Hu J, Xie L, Rao Z, Wang Y, Wang X, Qin CF. Natl Sci Rev 8 nwaa297 (2021)
  204. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Li H, Zhang Y, Li D, Deng YQ, Xu H, Zhao C, Liu J, Wen D, Zhao J, Li Y, Wu Y, Liu S, Liu J, Hao J, Yuan F, Duo S, Qin CF, Zheng A. Signal Transduct Target Ther 6 389 (2021)
  205. Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant. Akache B, Renner TM, Tran A, Deschatelets L, Dudani R, Harrison BA, Duque D, Haukenfrers J, Rossotti MA, Gaudreault F, Hemraz UD, Lam E, Régnier S, Chen W, Gervais C, Stuible M, Krishnan L, Durocher Y, McCluskie MJ. Sci Rep 11 21849 (2021)
  206. MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern. Wang J, Yin XG, Wen Y, Lu J, Zhang RY, Zhou SH, Liao CM, Wei HW, Guo J. J Med Chem 65 3563-3574 (2022)
  207. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus. Oberemok VV, Laikova KV, Yurchenko KA, Marochkin NA, Fomochkina II, Kubyshkin AV. Inflamm Res 69 801-812 (2020)
  208. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization. Pierce BG, Keck ZY, Wang R, Lau P, Garagusi K, Elkholy K, Toth EA, Urbanowicz RA, Guest JD, Agnihotri P, Kerzic MC, Marin A, Andrianov AK, Ball JK, Mariuzza RA, Fuerst TR, Foung SKH. J Virol 94 e00704-20 (2020)
  209. Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems. Merkuleva IA, Shcherbakov DN, Borgoyakova MB, Shanshin DV, Rudometov AP, Karpenko LI, Belenkaya SV, Isaeva AA, Nesmeyanova VS, Kazachinskaia EI, Volosnikova EA, Esina TI, Zaykovskaya AV, Pyankov OV, Borisevich SS, Shelemba AA, Chikaev AN, Ilyichev AA. Vaccines (Basel) 10 96 (2022)
  210. Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses. Chuang GY, Lai YT, Boyington JC, Cheng C, Geng H, Narpala S, Rawi R, Schmidt SD, Tsybovsky Y, Verardi R, Xu K, Yang Y, Zhang B, Chambers M, Changela A, Corrigan AR, Kong R, Olia AS, Ou L, Sarfo EK, Wang S, Wu W, Doria-Rose NA, McDermott AB, Mascola JR, Kwong PD. J Virol 94 e00074-20 (2020)
  211. Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic. Chawla H, Jossi SE, Faustini SE, Samsudin F, Allen JD, Watanabe Y, Newby ML, Marcial-Juárez E, Lamerton RE, McLellan JS, Bond PJ, Richter AG, Cunningham AF, Crispin M. J Mol Biol 434 167332 (2022)
  212. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity. Bowman KA, Stein D, Shin S, Ferbas KG, Tobin NH, Mann C, Fischinger S, Ollmann Saphire E, Lauffenburger D, Rimoin AW, Aldrovandi G, Alter G. mBio 13 e0164722 (2022)
  213. A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Weidenbacher PA, Sanyal M, Friedland N, Tang S, Arunachalam PS, Hu M, Kumru OS, Morris MK, Fontenot J, Shirreff L, Do J, Cheng YC, Vasudevan G, Feinberg MB, Villinger FJ, Hanson C, Joshi SB, Volkin DB, Pulendran B, Kim PS. Nat Commun 14 2149 (2023)
  214. Combination of Biodata Mining and Computational Modelling in Identification and Characterization of ORF1ab Polyprotein of SARS-CoV-2 Isolated from Oronasopharynx of an Iranian Patient. Zolfaghari Emameh R, Nosrati H, Taheri RA. Biol Proced Online 22 8 (2020)
  215. Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes. Fedechkin SO, George NL, Nuñez Castrejon AM, Dillen JR, Kauvar LM, DuBois RM. J Virol 94 e01879-19 (2020)
  216. The sprint to solve coronavirus protein structures - and disarm them with drugs. Scudellari M. Nature 581 252-255 (2020)
  217. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection. Pérez P, Lázaro-Frías A, Zamora C, Sánchez-Cordón PJ, Astorgano D, Luczkowiak J, Delgado R, Casasnovas JM, Esteban M, García-Arriaza J. Front Immunol 12 824728 (2021)
  218. A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera. Seephetdee C, Bhukhai K, Buasri N, Leelukkanaveera P, Lerdwattanasombat P, Manopwisedjaroen S, Phueakphud N, Kuhaudomlarp S, Olmedillas E, Saphire EO, Thitithanyanont A, Hongeng S, Wongtrakoongate P. Antiviral Res 204 105370 (2022)
  219. BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19. Ji RR, Qu Y, Zhu H, Yang Y, Vogel AB, Sahin U, Qin C, Hui A. Vaccines (Basel) 9 324 (2021)
  220. Cryo-EM analysis of the HCoV-229E spike glycoprotein reveals dynamic prefusion conformational changes. Song X, Shi Y, Ding W, Niu T, Sun L, Tan Y, Chen Y, Shi J, Xiong Q, Huang X, Huang X, Xiao S, Zhu Y, Cheng C, Fu ZF, Liu ZJ, Peng G. Nat Commun 12 141 (2021)
  221. Cryo-electron Microscopy Structure of the Swine Acute Diarrhea Syndrome Coronavirus Spike Glycoprotein Provides Insights into Evolution of Unique Coronavirus Spike Proteins. Guan H, Wang Y, Perčulija V, Saeed AFUH, Liu Y, Li J, Jan SS, Li Y, Zhu P, Ouyang S. J Virol 94 e01301-20 (2020)
  222. Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate. Sliepen K, Radić L, Capella-Pujol J, Watanabe Y, Zon I, Chumbe A, Lee WH, de Gast M, Koopsen J, Koekkoek S, Del Moral-Sánchez I, Brouwer PJM, Ravichandran R, Ozorowski G, King NP, Ward AB, van Gils MJ, Crispin M, Schinkel J, Sanders RW. Nat Commun 13 7271 (2022)
  223. One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model. Gooch KE, Smith TRF, Salguero FJ, Fotheringham SA, Watson RJ, Dennis MJ, Handley A, Humphries HE, Longet S, Tipton T, Sarfas C, Sibley L, Slack GS, Rayner E, Ryan KA, Schultheis K, Ramos SJ, White A, Charlton S, Sharpe SA, Gleeson F, Humeau LM, Hall Y, Broderick KE, Carroll MW. Vaccine 39 4885-4894 (2021)
  224. Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice. Lai CY, To A, Ann S Wong T, Lieberman MM, Clements DE, Senda JT, Ball AH, Pessaint L, Andersen H, Furuyama W, Marzi A, Donini O, Lehrer AT. Vaccine X 100126 (2021)
  225. Structure-based design of stabilized recombinant influenza neuraminidase tetramers. Ellis D, Lederhofer J, Acton OJ, Tsybovsky Y, Kephart S, Yap C, Gillespie RA, Creanga A, Olshefsky A, Stephens T, Pettie D, Murphy M, Sydeman C, Ahlrichs M, Chan S, Borst AJ, Park YJ, Lee KK, Graham BS, Veesler D, King NP, Kanekiyo M. Nat Commun 13 1825 (2022)
  226. Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses. McLeod B, Mabrouk MT, Miura K, Ravichandran R, Kephart S, Hailemariam S, Pham TP, Semesi A, Kucharska I, Kundu P, Huang WC, Johnson M, Blackstone A, Pettie D, Murphy M, Kraft JC, Leaf EM, Jiao Y, van de Vegte-Bolmer M, van Gemert GJ, Ramjith J, King CR, MacGill RS, Wu Y, Lee KK, Jore MM, King NP, Lovell JF, Julien JP. Immunity 55 1680-1692.e8 (2022)
  227. A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters. Frantz PN, Barinov A, Ruffié C, Combredet C, Najburg V, de Melo GD, Larrous F, Kergoat L, Teeravechyan S, Jongkaewwattana A, Billon-Denis E, Tournier JN, Prot M, Levillayer L, Conquet L, Montagutelli X, Tichit M, Hardy D, Fernandes P, Strick-Marchand H, Di Santo J, Simon-Lorière E, Bourhy H, Tangy F. Nat Commun 12 6277 (2021)
  228. Exploring the Regulatory Function of the N-terminal Domain of SARS-CoV-2 Spike Protein through Molecular Dynamics Simulation. Li Y, Wang T, Zhang J, Shao B, Gong H, Wang Y, He X, Liu S, Liu TY. Adv Theory Simul 4 2100152 (2021)
  229. Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers. Jackson-Thompson BM, Goguet E, Laing ED, Olsen CH, Pollett S, Hollis-Perry KM, Maiolatesi SE, Illinik L, Ramsey KF, Reyes AE, Alcorta Y, Wong MA, Davies J, Ortega O, Parmelee E, Lindrose AR, Moser M, Graydon E, Letizia AG, Duplessis CA, Ganesan A, Pratt KP, Malloy AM, Scott DW, Anderson SK, Snow AL, Dalgard CL, Powers JH, Tribble D, Burgess TH, Broder CC, Mitre E. BMC Infect Dis 21 544 (2021)
  230. Temperature effect on the SARS-CoV-2: A molecular dynamics study of the spike homotrimeric glycoprotein. Martí D, Torras J, Bertran O, Turon P, Alemán C. Comput Struct Biotechnol J 19 1848-1862 (2021)
  231. Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens. Kraft JC, Pham MN, Shehata L, Brinkkemper M, Boyoglu-Barnum S, Sprouse KR, Walls AC, Cheng S, Murphy M, Pettie D, Ahlrichs M, Sydeman C, Johnson M, Blackstone A, Ellis D, Ravichandran R, Fiala B, Wrenn S, Miranda M, Sliepen K, Brouwer PJM, Antanasijevic A, Veesler D, Ward AB, Kanekiyo M, Pepper M, Sanders RW, King NP. Cell Rep Med 3 100780 (2022)
  232. DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2. Parzych EM, Du J, Ali AR, Schultheis K, Frase D, Smith TRF, Cui J, Chokkalingam N, Tursi NJ, Andrade VM, Warner BM, Gary EN, Li Y, Choi J, Eisenhauer J, Maricic I, Kulkarni A, Chu JD, Villafana G, Rosenthal K, Ren K, Francica JR, Wootton SK, Tebas P, Kobasa D, Broderick KE, Boyer JD, Esser MT, Pallesen J, Kulp DW, Patel A, Weiner DB. Nat Commun 13 5886 (2022)
  233. Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants. Kuo CW, Yang TJ, Chien YC, Yu PY, Hsu SD, Khoo KH. Glycobiology 32 60-72 (2022)
  234. Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2. Seephetdee C, Buasri N, Bhukhai K, Srisanga K, Manopwisedjaroen S, Lertjintanakit S, Phueakphud N, Pakiranay C, Kangwanrangsan N, Srichatrapimuk S, Kirdlarp S, Sungkanuparph S, Chutipongtanate S, Thitithanyanont A, Hongeng S, Wongtrakoongate P. Vaccines (Basel) 9 498 (2021)
  235. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. Tostanoski LH, Gralinski LE, Martinez DR, Schaefer A, Mahrokhian SH, Li Z, Nampanya F, Wan H, Yu J, Chang A, Liu J, McMahan K, Ventura JD, Dinnon KH, Leist SR, Baric RS, Barouch DH. J Virol 95 e0097421 (2021)
  236. Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity. Meyer Zu Natrup C, Tscherne A, Dahlke C, Ciurkiewicz M, Shin DL, Fathi A, Rohde C, Kalodimou G, Halwe S, Limpinsel L, Schwarz JH, Klug M, Esen M, Schneiderhan-Marra N, Dulovic A, Kupke A, Brosinski K, Clever S, Schünemann LM, Beythien G, Armando F, Mayer L, Weskamm ML, Jany S, Freudenstein A, Tuchel T, Baumgärtner W, Kremsner P, Fendel R, Addo MM, Becker S, Sutter G, Volz A. J Clin Invest 132 e159895 (2022)
  237. Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein. Calvaresi V, Wrobel AG, Toporowska J, Hammerschmid D, Doores KJ, Bradshaw RT, Parsons RB, Benton DJ, Roustan C, Reading E, Malim MH, Gamblin SJ, Politis A. Nat Commun 14 1421 (2023)
  238. A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19. Chen CJ, Yang LY, Chang WY, Huang YC, Chiu CH, Shih SR, Huang CG, Huang KA. Nat Commun 13 5466 (2022)
  239. Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. Rosati M, Agarwal M, Hu X, Devasundaram S, Stellas D, Chowdhury B, Bear J, Burns R, Donohue D, Pessaint L, Andersen H, Lewis MG, Terpos E, Dimopoulos MA, Wlodawer A, Mullins JI, Venzon DJ, Pavlakis GN, Felber BK. PLoS Pathog 17 e1009701 (2021)
  240. DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice. Szurgot I, Hanke L, Sheward DJ, Vidakovics LP, Murrell B, McInerney GM, Liljeström P. Sci Rep 11 3125 (2021)
  241. Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice. Walls AC, VanBlargan LA, Wu K, Choi A, Navarro MJ, Lee D, Avena L, Berrueta DM, Pham MN, Elbashir S, Kraft JC, Miranda MC, Kepl E, Johnson M, Blackstone A, Sprouse K, Fiala B, O'Connor MA, Brunette N, Arunachalam PS, Shirreff L, Rogers K, Carter L, Fuller DH, Villinger F, Pulendran B, Diamond MS, Edwards DK, King NP, Veesler D. Cell Rep 40 111299 (2022)
  242. Letter Gene therapy avenues and COVID-19 vaccines. Abu Abed OS. Genes Immun 22 120-124 (2021)
  243. Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters. Stark FC, Akache B, Deschatelets L, Tran A, Stuible M, Durocher Y, McCluskie MJ, Agbayani G, Dudani R, Harrison BA, Renner TM, Makinen SR, Bavananthasivam J, Duque D, Gagne M, Zimmermann J, Zarley CD, Cochrane TR, Handfield M. Sci Rep 12 9772 (2022)
  244. Pre-existing immunity modulates responses to mRNA boosters. Dangi T, Sanchez S, Lew MH, Awakoaiye B, Visvabharathy L, Richner JM, Koralnik IJ, Penaloza-MacMaster P. Cell Rep 42 112167 (2023)
  245. Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display. Tanaka S, Olson CA, Barnes CO, Higashide W, Gonzalez M, Taft J, Richardson A, Martin-Fernandez M, Bogunovic D, Gnanapragasam PNP, Bjorkman PJ, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P. Cell Rep 38 110348 (2022)
  246. Selection and Characterization of Monoclonal Antibodies Targeting Middle East Respiratory Syndrome Coronavirus through a Human Synthetic Fab Phage Display Library Panning. Kim Y, Lee H, Park K, Park S, Lim JH, So MK, Woo HM, Ko H, Lee JM, Lim SH, Ko BJ, Park YS, Choi SY, Song DH, Lee JY, Kim SS, Kim DY. Antibodies (Basel) 8 E42 (2019)
  247. Structural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env. Hodge EA, Naika GS, Kephart SM, Nguyen A, Zhu R, Benhaim MA, Guo W, Moore JP, Hu SL, Sanders RW, Lee KK. iScience 25 104449 (2022)
  248. Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2. Song D, Wang W, Dong C, Ning Z, Liu X, Liu C, Du G, Sha C, Wang K, Lu J, Sun B, Zhao Y, Wang Q, Xu H, Li Y, Shen Z, Jiao J, Wang R, Tian J, Liu W, Wang L, Deng YQ, Dou C. Commun Biol 4 500 (2021)
  249. Deciphering the protein motion of S1 subunit in SARS-CoV-2 spike glycoprotein through integrated computational methods. Tian H, Tao P. J Biomol Struct Dyn 39 6705-6712 (2021)
  250. Development of an in silico multi-epitope vaccine against SARS-COV-2 by précised immune-informatics approaches. Al Zamane S, Nobel FA, Jebin RA, Amin MB, Somadder PD, Antora NJ, Hossain MI, Islam MJ, Ahmed K, Moni MA. Inform Med Unlocked 27 100781 (2021)
  251. High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers. Del Moral-Sánchez I, Russell RA, Schermer EE, Cottrell CA, Allen JD, Torrents de la Peña A, LaBranche CC, Kumar S, Crispin M, Ward AB, Montefiori DC, Sattentau QJ, Sliepen K, Sanders RW. NPJ Vaccines 7 27 (2022)
  252. High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike. Tan TJC, Mou Z, Lei R, Ouyang WO, Yuan M, Song G, Andrabi R, Wilson IA, Kieffer C, Dai X, Matreyek KA, Wu NC. Nat Commun 14 2003 (2023)
  253. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization. Gu M, Torres JL, Li Y, Van Ry A, Greenhouse J, Wallace S, Chiang CI, Pessaint L, Jackson AM, Porto M, Kar S, Li Y, Ward AB, Wang Y. Emerg Microbes Infect 10 2016-2029 (2021)
  254. Plasma From Recovered COVID-19 Patients Inhibits Spike Protein Binding to ACE2 in a Microsphere-Based Inhibition Assay. Gniffke EP, Harrington WE, Dambrauskas N, Jiang Y, Trakhimets O, Vigdorovich V, Frenkel L, Sather DN, Smith SEP. J Infect Dis 222 1965-1973 (2020)
  255. RCSB Protein Data Bank resources for structure-facilitated design of mRNA vaccines for existing and emerging viral pathogens. Goodsell DS, Burley SK. Structure 30 55-68.e2 (2022)
  256. Structure-Based Stabilization of SOSIP Env Enhances Recombinant Ectodomain Durability and Yield. Wrapp D, Mu Z, Thakur B, Janowska K, Ajayi O, Barr M, Parks R, Mansouri K, Edwards RJ, Hahn BH, Acharya P, Saunders KO, Haynes BF. J Virol 97 e0167322 (2023)
  257. Suppression of O-Linked Glycosylation of the SARS-CoV-2 Spike by Quaternary Structural Restraints. Eldrid CFS, Allen JD, Newby ML, Crispin M. Anal Chem 93 14392-14400 (2021)
  258. Timeline of changes in spike conformational dynamics in emergent SARS-CoV-2 variants reveal progressive stabilization of trimer stalk with altered NTD dynamics. Braet SM, Buckley TSC, Venkatakrishnan V, Dam KA, Bjorkman PJ, Anand GS. Elife 12 e82584 (2023)
  259. A 3.4-Å cryo-electron microscopy structure of the human coronavirus spike trimer computationally derived from vitrified NL63 virus particles. Zhang K, Li S, Pintilie G, Chmielewski D, Schmid MF, Simmons G, Jin J, Chiu W. QRB Discov 1 e11 (2020)
  260. A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability. Voigt EA, Gerhardt A, Hanson D, Jennewein MF, Battisti P, Reed S, Singh J, Mohamath R, Bakken J, Beaver S, Press C, Soon-Shiong P, Paddon CJ, Fox CB, Casper C. NPJ Vaccines 7 136 (2022)
  261. How Did We Get a COVID-19 Vaccine in Less Than 1 Year? Wherry EJ, Jaffee EM, Warren N, D'Souza G, Ribas A, AACR COVID-19 and Cancer Task Force. Clin Cancer Res 27 2136-2138 (2021)
  262. Case Reports Immune thrombocytopenia purpura flare post COVID-19 vaccine. A Ali E, Al-Maharmeh Q, Rozi WM, Habib MB, Yassin M. Ann Med Surg (Lond) 75 103164 (2022)
  263. Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys. Hashimoto M, Nagata N, Homma T, Maeda H, Dohi K, Seki NM, Yoshihara K, Iwata-Yoshikawa N, Shiwa-Sudo N, Sakai Y, Shirakura M, Kishida N, Arita T, Suzuki Y, Watanabe S, Asanuma H, Sonoyama T, Suzuki T, Omoto S, Hasegawa H. Vaccine 40 4231-4241 (2022)
  264. Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern. Akache B, Renner TM, Stuible M, Rohani N, Cepero-Donates Y, Deschatelets L, Dudani R, Harrison BA, Gervais C, Hill JJ, Hemraz UD, Lam E, Régnier S, Lenferink AEG, Durocher Y, McCluskie MJ. NPJ Vaccines 7 118 (2022)
  265. In situ structure and dynamics of an alphacoronavirus spike protein by cryo-ET and cryo-EM. Huang CY, Draczkowski P, Wang YS, Chang CY, Chien YC, Cheng YH, Wu YM, Wang CH, Chang YC, Chang YC, Yang TJ, Tsai YX, Khoo KH, Chang HW, Hsu SD. Nat Commun 13 4877 (2022)
  266. Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models. Palladino G, Chang C, Lee C, Music N, De Souza I, Nolasco J, Amoah S, Suphaphiphat P, Otten GR, Settembre EC, Wen Y. Mol Ther Methods Clin Dev 25 225-235 (2022)
  267. Stabilization of the SARS-CoV-2 receptor binding domain by protein core redesign and deep mutational scanning. Leonard AC, Weinstein JJ, Steiner PJ, Erbse AH, Fleishman SJ, Whitehead TA. Protein Eng Des Sel 35 gzac002 (2022)
  268. Tall tails: cryo-electron microscopy of phage tail DNA ejection conduits. Hardy JM, Dunstan RA, Lithgow T, Coulibaly F. Biochem Soc Trans 50 459-22W (2022)
  269. A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike. van der Velden YU, Grobben M, Caniels TG, Burger JA, Poniman M, Oomen M, Rijnstra ES, Tejjani K, Guerra D, Kempers R, Stegmann T, van Gils MJ, Sanders RW. Sci Rep 12 3884 (2022)
  270. Antibody Response to Severe Acute Respiratory Syndrome- Corona Virus 2, Diagnostic and Therapeutic Implications. Ishay Y, Kessler A, Schwarts A, Ilan Y. Hepatol Commun 4 1731-1743 (2020)
  271. Chimeric Pneumoviridae fusion proteins as immunogens to induce cross-neutralizing antibody responses. Olmedillas E, Cano O, Martínez I, Luque D, Terrón MC, McLellan JS, Melero JA, Más V. EMBO Mol Med 10 175-187 (2018)
  272. Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein. Choi JA, Goo J, Yang E, Jung DI, Lee S, Rho S, Jeong Y, Park YS, Park H, Moon YH, Park U, Seo SH, Lee H, Lee JM, Cho NH, Song M, Kim JO. J Virol 94 e01176-20 (2020)
  273. Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. Hansen L, Brokstad KA, Bansal A, Zhou F, Bredholt G, Onyango TB, Sandnes HH, Elyanow R, Madsen A, Trieu MC, Sævik M, Søyland H, Olofsson JS, Vahokoski J, Ertesvåg NU, Fjelltveit EB, Shafiani S, Tøndel C, Chapman H, Kaplan I, Mohn KGI, Langeland N, Cox RJ. Vaccine X 13 100262 (2023)
  274. Immunology of SARS-CoV-2 infections and vaccines. Schenten D, Bhattacharya D. Adv Immunol 151 49-97 (2021)
  275. Investigating Constraints Along the Plant Secretory Pathway to Improve Production of a SARS-CoV-2 Spike Vaccine Candidate. Margolin E, Verbeek M, de Moor W, Chapman R, Meyers A, Schäfer G, Williamson AL, Rybicki E. Front Plant Sci 12 798822 (2021)
  276. Large-scale design and refinement of stable proteins using sequence-only models. Singer JM, Novotney S, Strickland D, Haddox HK, Leiby N, Rocklin GJ, Chow CM, Roy A, Bera AK, Motta FC, Cao L, Strauch EM, Chidyausiku TM, Ford A, Ho E, Zaitzeff A, Mackenzie CO, Eramian H, DiMaio F, Grigoryan G, Vaughn M, Stewart LJ, Baker D, Klavins E. PLoS One 17 e0265020 (2022)
  277. Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity. Liao HC, Wu WL, Chiang CY, Huang MS, Shen KY, Huang YL, Wu SC, Liao CL, Chen HW, Liu SJ. Int J Mol Sci 23 4902 (2022)
  278. Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. Ohtsuka J, Imai M, Fukumura M, Maeda M, Eguchi A, Ono R, Maemura T, Ito M, Yamayoshi S, Kataoka Y, Kawaoka Y, Nosaka T. iScience 24 103379 (2021)
  279. Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2. Shahrajabian MH, Sun W, Cheng Q. Hum Vaccin Immunother 17 62-83 (2021)
  280. Rapid Response Subunit Vaccine Design in the Absence of Structural Information. Wijesundara DK, Avumegah MS, Lackenby J, Modhiran N, Isaacs A, Young PR, Watterson D, Chappell KJ. Front Immunol 11 592370 (2020)
  281. SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. Olia AS, Tsybovsky Y, Chen SJ, Liu C, Nazzari AF, Ou L, Wang L, Kong WP, Leung K, Liu T, Stephens T, Teng IT, Wang S, Yang ES, Zhang B, Zhang Y, Zhou T, Mascola JR, Kwong PD. J Biol Chem 297 101127 (2021)
  282. Editorial Advances of mRNA vaccines for COVID-19: A new prophylactic revolution begins. Weng Y, Huang Y. Asian J Pharm Sci 16 263-264 (2021)
  283. Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. Choi JH, Woo HM, Lee TY, Lee SY, Shim SM, Park WJ, Yang JS, Kim JA, Yun MR, Kim DW, Kim SS, Zhang Y, Shi W, Wang L, Graham BS, Mascola JR, Wang N, McLellan JS, Lee JY, Lee H. PLoS One 15 e0232757 (2020)
  284. ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines. Hoffmann MAG, Yang Z, Huey-Tubman KE, Cohen AA, Gnanapragasam PNP, Nakatomi LM, Storm KN, Moon WJ, Lin PJC, West AP, Bjorkman PJ. Cell 186 2380-2391.e9 (2023)
  285. Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins. Shi Y, Shi J, Sun L, Tan Y, Wang G, Guo F, Hu G, Fu Y, Fu ZF, Xiao S, Peng G. J Virol 95 JVI.02284-20 (2021)
  286. Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies. Zhong C, Xia H, Adam A, Wang B, Hajnik RL, Liang Y, Rafael GH, Zou J, Wang X, Sun J, Soong L, Barrett ADT, Weaver SC, Shi PY, Wang T, Hu H. NPJ Vaccines 6 139 (2021)
  287. Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species. Peng L, Fang Z, Renauer PA, McNamara A, Park JJ, Lin Q, Zhou X, Dong MB, Zhu B, Zhao H, Wilen CB, Chen S. Cell Rep 40 111160 (2022)
  288. Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses. Roth N, Schön J, Hoffmann D, Thran M, Thess A, Mueller SO, Petsch B, Rauch S. Vaccines (Basel) 10 1251 (2022)
  289. Piglet immunization with a spike subunit vaccine enhances disease by porcine epidemic diarrhea virus. Yu J, Sreenivasan C, Uprety T, Gao R, Huang C, Lee EJ, Lawson S, Nelson J, Christopher-Hennings J, Kaushik RS, Nelson E, Diel DG, Hause BM, Li F, Wang D. NPJ Vaccines 6 22 (2021)
  290. Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2. Barreiro A, Prenafeta A, Bech-Sabat G, Roca M, Perozo Mur E, March R, González-González L, Madrenas L, Corominas J, Fernández A, Moros A, Cañete M, Molas M, Pentinat-Pelegrin T, Panosa C, Moreno A, Puigvert Molas E, Pol Vilarrassa E, Palmada J, Garriga C, Prat Cabañas T, Iglesias-Fernández J, Vergara-Alert J, Lorca-Oró C, Roca N, Fernández-Bastit L, Rodon J, Pérez M, Segalés J, Pradenas E, Marfil S, Trinité B, Ortiz R, Clotet B, Blanco J, Díaz Pedroza J, Ampudia Carrasco R, Rosales Salgado Y, Loubat-Casanovas J, Capdevila Larripa S, Prado JG, Barretina J, Sisteré-Oró M, Cebollada Rica P, Meyerhans A, Ferrer L. iScience 26 106126 (2023)
  291. Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective. Baldwin J, Piplani S, Sakala IG, Honda-Okubo Y, Li L, Petrovsky N. Bioanalysis 13 1805-1826 (2021)
  292. Tackling Covid-19 using disordered-to-order transition of residues in the spike protein upon angiotensin-converting enzyme 2 binding. Yesudhas D, Srivastava A, Sekijima M, Gromiha MM. Proteins 89 1158-1166 (2021)
  293. A platform technology for generating subunit vaccines against diverse viral pathogens. Young A, Isaacs A, Scott CAP, Modhiran N, McMillan CLD, Cheung STM, Barr J, Marsh G, Thakur N, Bailey D, Li KSM, Luk HKH, Kok KH, Lau SKP, Woo PCY, Furuyama W, Marzi A, Young PR, Chappell KJ, Watterson D. Front Immunol 13 963023 (2022)
  294. Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects. Lazebnik Y. Oncotarget 12 2476-2488 (2021)
  295. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses. Brinkkemper M, Veth TS, Brouwer PJM, Turner H, Poniman M, Burger JA, Bouhuijs JH, Olijhoek W, Bontjer I, Snitselaar JL, Caniels TG, van der Linden CA, Ravichandran R, Villaudy J, van der Velden YU, Sliepen K, van Gils MJ, Ward AB, King NP, Heck AJR, Sanders RW. iScience 25 105649 (2022)
  296. Cryo-EM structures of prefusion SIV envelope trimer. Gorman J, Wang C, Mason RD, Nazzari AF, Welles HC, Zhou T, Bess JW, Bylund T, Lee M, Tsybovsky Y, Verardi R, Wang S, Yang Y, Zhang B, Rawi R, Keele BF, Lifson JD, Liu J, Roederer M, Kwong PD. Nat Struct Mol Biol 29 1080-1091 (2022)
  297. Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain. Takano T, Sato T, Kotaki R, Moriyama S, Fukushi S, Shinoda M, Kabasawa K, Shimada N, Kousaka M, Adachi Y, Onodera T, Terahara K, Isogawa M, Matsumura T, Shinkai M, Takahashi Y. Nat Commun 14 1451 (2023)
  298. Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice. Prompetchara E, Ketloy C, Alameh MG, Tharakhet K, Kaewpang P, Yostrerat N, Pitakpolrat P, Buranapraditkun S, Manopwisedjaroen S, Thitithanyanont A, Jongkaewwattana A, Hunsawong T, Im-Erbsin R, Reed M, Wijagkanalan W, Patarakul K, Techawiwattanaboon T, Palaga T, Lam K, Heyes J, Weissman D, Ruxrungtham K. Nat Commun 14 2309 (2023)
  299. Improving the secretion of designed protein assemblies through negative design of cryptic transmembrane domains. Wang JYJ, Khmelinskaia A, Sheffler W, Miranda MC, Antanasijevic A, Borst AJ, Torres SV, Shu C, Hsia Y, Nattermann U, Ellis D, Walkey C, Ahlrichs M, Chan S, Kang A, Nguyen H, Sydeman C, Sankaran B, Wu M, Bera AK, Carter L, Fiala B, Murphy M, Baker D, Ward AB, King NP. Proc Natl Acad Sci U S A 120 e2214556120 (2023)
  300. Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape. Marzi R, Bassi J, Silacci-Fregni C, Bartha I, Muoio F, Culap K, Sprugasci N, Lombardo G, Saliba C, Cameroni E, Cassotta A, Low JS, Walls AC, McCallum M, Tortorici MA, Bowen JE, Dellota EA, Dillen JR, Czudnochowski N, Pertusini L, Terrot T, Lepori V, Tarkowski M, Riva A, Biggiogero M, Franzetti-Pellanda A, Garzoni C, Ferrari P, Ceschi A, Giannini O, Havenar-Daughton C, Telenti A, Arvin A, Virgin HW, Sallusto F, Veesler D, Lanzavecchia A, Corti D, Piccoli L. iScience 26 105726 (2023)
  301. Modeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape. Kunkel G, Madani M, White SJ, Verardi PH, Tarakanova A. Biophys J 120 5592-5618 (2021)
  302. Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice. Paschall AV, Ozdilek A, Briner SL, Brindley MA, Avci FY. Vaccine 40 854-861 (2022)
  303. Prevalence and mechanisms of evolutionary contingency in human influenza H3N2 neuraminidase. Lei R, Tan TJC, Hernandez Garcia A, Wang Y, Diefenbacher M, Teo C, Gopan G, Tavakoli Dargani Z, Teo QW, Graham CS, Brooke CB, Nair SK, Wu NC. Nat Commun 13 6443 (2022)
  304. Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study. Sáez-Llorens X, Lanata C, Aranguren E, Celis CR, Cornejo R, DeAntonio R, Ecker L, Garrido D, Gil AI, Gonzales M, Hess-Holtz M, Leroux-Roels G, Junker H, Kays SK, Koch SD, Lazzaro S, Mann P, Quintini G, Srivastava B, Vahrenhorst D, von Eisenhart-Rothe P, Wolz OO, Oostvogels L. Vaccine X 11 100189 (2022)
  305. Severe Clinical Worsening in COVID-19 and Potential Mechanisms of Immune-Enhanced Disease. Hussman JP. Front Med (Lausanne) 8 637642 (2021)
  306. The Race to Develop the Pfizer-BioNTech COVID-19 Vaccine: From the Pharmaceutical Scientists' Perspective. Lewis LM, Badkar AV, Cirelli D, Combs R, Lerch TF. J Pharm Sci 112 640-647 (2023)
  307. What the Moderna-NIH COVID vaccine patent fight means for research. Ledford H. Nature 600 200-201 (2021)
  308. X-ray Structures of the Post-fusion 6-Helix Bundle of the Human Syncytins and their Functional Implications. Ruigrok K, Vaney MC, Buchrieser J, Baquero E, Hellert J, Baron B, England P, Schwartz O, Rey FA, Backovic M. J Mol Biol 431 4922-4940 (2019)
  309. A New Strategy Coupling Ion-Mobility-Selective CID and Cryogenic IR Spectroscopy to Identify Glycan Anomers. Pellegrinelli RP, Yue L, Carrascosa E, Ben Faleh A, Warnke S, Bansal P, Rizzo TR. J Am Soc Mass Spectrom 33 859-864 (2022)
  310. COVID-19 vaccine design using reverse and structural vaccinology, ontology-based literature mining and machine learning. Huffman A, Ong E, Hur J, D'Mello A, Tettelin H, He Y. Brief Bioinform 23 bbac190 (2022)
  311. Characterization of a SARS-CoV-2 spike protein reference material. Stocks BB, Thibeault MP, Schrag JD, Melanson JE. Anal Bioanal Chem 414 3561-3569 (2022)
  312. FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein. Miller CJ, McGinnis JE, Martinez MJ, Wang G, Zhou J, Simmons E, Amet T, Abdeen SJ, Van Huysse JW, Bowsher RR, Kay BK. N Biotechnol 62 79-85 (2021)
  313. Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein. Ozharovskaia TA, Zubkova OV, Dolzhikova IV, Gromova AS, Grousova DM, Tukhvatulin AI, Popova O, Shcheblyakov DV, Scherbinin DN, Dzharullaeva AS, Erokhova AS, Shmarov MM, Loginova SY, Borisevich SV, Naroditsky BS, Logunov DY, Gintsburg AL. Acta Naturae 11 38-47 (2019)
  314. Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2. Park HS, Matsuoka Y, Luongo C, Yang L, Santos C, Liu X, Ahlers LRH, Moore IN, Afroz S, Johnson RF, Lafont BAP, Dorward DW, Fischer ER, Martens C, Samal SK, Munir S, Buchholz UJ, Le Nouën C. NPJ Vaccines 7 72 (2022)
  315. Pandemic Vaccines: How Are We Going to Be Better Prepared Next Time? Krammer F. Med 1 28-32 (2020)
  316. Production and secretion of functional SARS-CoV-2 spike protein in Chlamydomonas reinhardtii. Kiefer AM, Niemeyer J, Probst A, Erkel G, Schroda M. Front Plant Sci 13 988870 (2022)
  317. Relevance of immune response and vaccination strategies of SARS-CoV-2 in the phase of viral red queen dynamics. Jacob JJ, John Fletcher G, Monisha Priya T, Veeraraghavan B, Mutreja A. Indian J Med Microbiol 39 417-422 (2021)
  318. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease. Deschambault Y, Lynch J, Warner B, Tierney K, Huynh D, Vendramelli R, Tailor N, Frost K, Sajesh B, LeBlanc K, Layne C, Lin L, Tamming L, Beniac D, Booth S, Carpenter M, Safronetz D, Li X, Kobasa D, Cao J. J Virol 96 e0038922 (2022)
  319. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice. Hu L, Xu Y, Wu L, Feng J, Zhang L, Tang Y, Zhao X, Mai R, Chen L, Mei L, Tan Y, Du Y, Zhen Y, Su W, Peng T. Viruses 14 854 (2022)
  320. "Just in Time": The Role of Cryo-Electron Microscopy in Combating Recent Pandemics. Frank J. Biochemistry 60 3449-3451 (2021)
  321. Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice. Jang Y, Cho H, Chun J, Park K, Nowakowska A, Kim J, Lee H, Lee C, Han Y, Lee HJ, Shin HY, Kim YB. Vaccine 41 1223-1231 (2023)
  322. Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes. Hein S, Benz NI, Eisert J, Herrlein ML, Oberle D, Dreher M, Stingl JC, Hildt C, Hildt E. Vaccines (Basel) 9 1419 (2021)
  323. Detection of MERS-CoV antigen on formalin-fixed paraffin-embedded nasal tissue of alpacas by immunohistochemistry using human monoclonal antibodies directed against different epitopes of the spike protein. Haverkamp AK, Bosch BJ, Spitzbarth I, Lehmbecker A, Te N, Bensaid A, Segalés J, Baumgärtner W. Vet Immunol Immunopathol 218 109939 (2019)
  324. Determination of human COVID-19 total antibodies in serum using a time-resolved fluorescence immunoassay. Xu Y, Chen C, Lai H, He Y, Guo G, Feng J, Li L. Biotechnol Appl Biochem 69 1474-1481 (2022)
  325. Evaluation of antibody titer kinetics and SARS-CoV-2 infections in a large cohort of healthcare professionals ten months after administration of the BNT162b2 vaccine. Ferrari D, Ambrosi A, Di Resta C, Tomaiuolo R, Locatelli M, Banfi G. J Immunol Methods 506 113293 (2022)
  326. GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial. Capone S, Fusco FM, Milleri S, Borrè S, Carbonara S, Lo Caputo S, Leone S, Gori G, Maggi P, Cascio A, Lichtner M, Cauda R, Dal Zoppo S, Cossu MV, Gori A, Roda S, Confalonieri P, Bonora S, Missale G, Codeluppi M, Mezzaroma I, Capici S, Pontali E, Libanore M, Diani A, Lanini S, Battella S, Contino AM, Piano Mortari E, Genova F, Parente G, Dragonetti R, Colloca S, Visani L, Iannacone C, Carsetti R, Folgori A, Camerini R, COVITAR study group. Cell Rep Med 4 101084 (2023)
  327. Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2. Resch MD, Wen K, Mazboudi R, Mulhall Maasz H, Persaud M, Garvey K, Gallardo L, Gottlieb P, Alimova A, Khayat R, Morales J, Bielefeldt-Ohmann H, Bowen RA, Galarza JM. Vaccines (Basel) 10 1997 (2022)
  328. Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits. O'Kennedy MM, Abolnik C, Smith T, Motlou T, Goosen K, Sepotokele KM, Roth R, du Preez I, Truyts A, Stark HC, Magwaza M, Mahanjana O, Verschoor JA, Moore PL, Lemmer Y. Vaccine 41 2261-2269 (2023)
  329. Intranasal delivery of a chimpanzee adenovirus vector expressing a pre-fusion spike (BV-AdCoV-1) protects golden Syrian hamsters against SARS-CoV-2 infection. Wang S, Xu L, Mu T, Qin M, Zhao P, Xie L, Du L, Wu Y, Legrand N, Mouchain K, Fichet G, Liu Y, Yin W, Zhao J, Ji M, Gong B, Klein M, Wu K. Front Cell Infect Microbiol 12 979641 (2022)
  330. Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant. Hayashi H, Sun J, Yanagida Y, Otera T, Sasai M, Chang CY, Tai JA, Nishikawa T, Yamashita K, Sakaguchi N, Yoshida S, Baba S, Shimamura M, Okamoto S, Amaishi Y, Chono H, Mineno J, Rakugi H, Morishita R, Yamamoto M, Nakagami H. Sci Rep 12 20923 (2022)
  331. Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera. Hutchinson GB, Abiona OM, Ziwawo CT, Werner AP, Ellis D, Tsybovsky Y, Leist SR, Palandjian C, West A, Fritch EJ, Wang N, Wrapp D, Boyoglu-Barnum S, Ueda G, Baker D, Kanekiyo M, McLellan JS, Baric RS, King NP, Graham BS, Corbett-Helaire KS. Nat Commun 14 6195 (2023)
  332. Prefusion spike protein stabilization through computational mutagenesis. Zhang DY, Wang J, Dokholyan NV. Proteins 89 399-408 (2021)
  333. SARS-CoV-2 spike trimer vaccine expressed in Nicotiana benthamiana adjuvanted with Alum elicits protective immune responses in mice. Song SJ, Kim H, Jang EY, Jeon H, Diao HP, Khan MRI, Lee MS, Lee YJ, Nam JH, Kim SR, Kim YJ, Sohn EJ, Hwang I, Choi JH. Plant Biotechnol J 20 2298-2312 (2022)
  334. Sialoglycan binding triggers spike opening in a human coronavirus. Pronker MF, Creutznacher R, Drulyte I, Hulswit RJG, Li Z, van Kuppeveld FJM, Snijder J, Lang Y, Bosch BJ, Boons GJ, Frank M, de Groot RJ, Hurdiss DL. Nature 624 201-206 (2023)
  335. Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization. McConnell SA, Sachithanandham J, Mudrak NJ, Zhu X, Farhang PA, Cordero RJB, Wear MP, Shapiro JR, Park HS, Klein SL, Tobian AAR, Bloch EM, Sullivan DJ, Pekosz A, Casadevall A. Cell Chem Biol 30 726-738.e4 (2023)
  336. Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models. Lorenzo MM, Marín-López A, Chiem K, Jimenez-Cabello L, Ullah I, Utrilla-Trigo S, Calvo-Pinilla E, Lorenzo G, Moreno S, Ye C, Park JG, Matía A, Brun A, Sánchez-Puig JM, Nogales A, Mothes W, Uchil PD, Kumar P, Ortego J, Fikrig E, Martinez-Sobrido L, Blasco R. Vaccines (Basel) 11 1006 (2023)
  337. mRNA-1273 vaccination protects against SARS-CoV-2-elicited lung inflammation in nonhuman primates. Waickman AT, Victor K, Newell K, Li T, Friberg H, Foulds KE, Roederer M, Bolton DL, Currier JR, Seder R. JCI Insight 7 e160039 (2022)
  338. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine. Estephan L, Liu LT, Lien CE, Smith ER, Gurwith M, Chen RT, Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO ex-V3SWG). Vaccine 41 2615-2629 (2023)
  339. Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern. McNamara RP, Maron JS, Boucau J, Roy V, Webb NE, Bertera HL, Barczak AK, Positives Study Staff T, Franko N, Logue JK, Kemp M, Li JZ, Zhou L, Hsieh CL, McLellan JS, Siedner MJ, Seaman MS, Lemieux JE, Chu HY, Alter G. mBio 14 e0090223 (2023)
  340. Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models. Roth N, Gergen J, Kovacikova K, Mueller SO, Ulrich L, Schön J, Halwe NJ, Fricke C, Corleis B, Dorhoi A, Hoffmann D, Beer M, Maione D, Petsch B, Rauch S. Vaccines (Basel) 11 318 (2023)
  341. Automatic and accurate ligand structure determination guided by cryo-electron microscopy maps. Muenks A, Zepeda S, Zhou G, Veesler D, DiMaio F. Nat Commun 14 1164 (2023)
  342. Baculovirus-expressed self-assembling SARS-CoV-2 nanoparticle vaccines targeting the S protein induce protective immunity in mice. Liu X, Song H, Jiang J, Gao X, Yi Y, Shang Y, Li J, Li D, Zeng Z, Li Y, Zhang Z. Process Biochem 129 200-208 (2023)
  343. Conserved Residues Adjacent to ß-Barrel and Loop Intersection among Enterovirus VP1 Affect Viral Replication: Potential Target for Anti-Enteroviral Development. Huang YL, Huang SW, Shen CY, Cheng D, Wang JR. Viruses 14 364 (2022)
  344. Coronavirus Entry Inhibitors. Lan Q, Xia S, Lu L. Adv Exp Med Biol 1366 101-121 (2022)
  345. Dynamic SARS-CoV-2 emergence algorithm for rationally-designed logical next-generation vaccines. Maison DP, Ching LL, Cleveland SB, Tseng AC, Nakano E, Shikuma CM, Nerurkar VR. Commun Biol 5 1081 (2022)
  346. Host susceptibility and structural and immunological insight of S proteins of two SARS-CoV-2 closely related bat coronaviruses. Ou X, Xu G, Li P, Liu Y, Zan F, Liu P, Hu J, Lu X, Dong S, Zhou Y, Mu Z, Wu Z, Wang J, Jin Q, Liu P, Lu J, Wang X, Qian Z. Cell Discov 9 78 (2023)
  347. Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. Yang MC, Wang CC, Tang WC, Chen KM, Chen CY, Lin HH, Hsieh YC, Wang NH, Kuo YC, Chu PT, Tung HY, Wu YC, Sun JL, Liu SY, Li WF, Lee WH, Lai JS, Chang M, Lai MT. PLoS One 18 e0283473 (2023)
  348. Insect cell expression and purification of recombinant SARS-COV-2 spike proteins that demonstrate ACE2 binding. Struble LR, Smith AL, Lutz WE, Grubbs G, Sagar S, Bayles KW, Radhakrishnan P, Khurana S, El-Gamal D, Borgstahl GEO. Protein Sci 31 e4300 (2022)
  349. Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report. Cable J, Fauci A, Dowling WE, Günther S, Bente DA, Yadav PD, Madoff LC, Wang LF, Arora RK, Van Kerkhove M, Chu MC, Jaenisch T, Epstein JH, Frost SDW, Bausch DG, Hensley LE, Bergeron É, Sitaras I, Gunn MD, Geisbert TW, Muñoz-Fontela C, Krammer F, de Wit E, Nordenfelt P, Saphire EO, Gilbert SC, Corbett KS, Branco LM, Baize S, van Doremalen N, Krieger MA, Clemens SAC, Hesselink R, Hartman D. Ann N Y Acad Sci 1518 209-225 (2022)
  350. Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230. Ivanochko D, Fabra-García A, Teelen K, van de Vegte-Bolmer M, van Gemert GJ, Newton J, Semesi A, de Bruijni M, Bolscher J, Ramjith J, Szabat M, Vogt S, Kraft L, Duncan S, Lee SM, Kamya MR, Feeney ME, Jagannathan P, Greenhouse B, Sauerwein RW, Richter King C, MacGill RS, Bousema T, Jore MM, Julien JP. Immunity 56 420-432.e7 (2023)
  351. Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines. Scaria PV, Rowe CG, Chen BB, Dickey TH, Renn JP, Lambert LE, Barnafo EK, Rausch KM, Tolia NH, Duffy PE. iScience 25 104739 (2022)
  352. Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring. Brady T, Zhang T, Tuffy KM, Haskins N, Du Q, Lin J, Kaplan G, Novick S, Roe TL, Ren K, Rosenthal K, McTamney PM, Abram ME, Streicher K, Kelly EJ. Microbiol Spectr 10 e0103422 (2022)
  353. SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model. Mucker EM, Brocato RL, Principe LM, Kim RK, Zeng X, Smith JM, Kwilas SA, Kim S, Horton H, Caproni L, Hooper JW. Vaccines (Basel) 10 1104 (2022)
  354. Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro. Nyagwange J, Kutima B, Mwai K, Karanja HK, Gitonga JN, Mugo D, Sein Y, Wright D, Omuoyo DO, Nyiro JU, Tuju J, Nokes DJ, Agweyu A, Bejon P, Ochola-Oyier LI, Scott JAG, Lambe T, Nduati E, Agoti C, Warimwe GM. Int J Infect Dis 127 11-16 (2023)
  355. Synthetic proteins for COVID-19 diagnostics. Schein CH, Levine CB, McLellan SLF, Negi SS, Braun W, Dreskin SC, Anaya ES, Schmidt J. Peptides 143 170583 (2021)
  356. The structure of a novel antibody against the spike protein inhibits Middle East respiratory syndrome coronavirus infections. Jang TH, Park WJ, Lee H, Woo HM, Lee SY, Kim KC, Kim SS, Hong E, Song J, Lee JY. Sci Rep 12 1260 (2022)
  357. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern. Renner TM, Akache B, Stuible M, Rohani N, Cepero-Donates Y, Deschatelets L, Dudani R, Harrison BA, Baardsnes J, Koyuturk I, Hill JJ, Hemraz UD, Régnier S, Lenferink AEG, Durocher Y, McCluskie MJ. Front Immunol 14 1182556 (2023)
  358. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273). Leav B, Straus W, White P, Leav A, Gaines T, Maggiacomo G, Kim D, Smith ER, Gurwith M, Chen RT, Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO ex-V3SWG. Vaccine 40 5275-5293 (2022)
  359. A COVID-19 vaccine candidate based on SARS-CoV-2 spike protein and immune-stimulating complexes. Villarraza J, Fuselli A, Gugliotta A, Garay E, Rodríguez MC, Fontana D, Antuña S, Gastaldi V, Battagliotti JM, Tardivo MB, Alvarez D, Castro E, Cassataro J, Ceaglio N, Prieto C. Appl Microbiol Biotechnol 107 3429-3441 (2023)
  360. A CTB-SARS-CoV-2-ACE-2 RBD Mucosal Vaccine Protects Against Coronavirus Infection. Dénes B, Fuller RN, Kelin W, Levin TR, Gil J, Harewood A, Lőrincz M, Wall NR, Firek AF, Langridge WHR. Vaccines (Basel) 11 1865 (2023)
  361. A genetically engineered, stem-cell-derived cellular vaccine. Cooper A, Sidaway A, Chandrashekar A, Latta E, Chakraborty K, Yu J, McMahan K, Giffin V, Manickam C, Kroll K, Mosher M, Reeves RK, Gam R, Arthofer E, Choudhry M, Henley T, Barouch DH. Cell Rep Med 3 100843 (2022)
  362. A novel C-terminal modification method enhanced the yield of human papillomavirus L1 or chimeric L1-L2 virus-like particles in the baculovirus system. Ma M, Xia B, Wang Z, Hao Y, Zhang T, Xu X. Front Bioeng Biotechnol 10 1073892 (2022)
  363. An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission. Li W, Wang T, Rajendrakumar AM, Acharya G, Miao Z, Varghese BP, Yu H, Dhakal B, LeRoith T, Karunakaran A, Tuo W, Zhu X. Nat Commun 14 7114 (2023)
  364. Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses. Radić L, Sliepen K, Yin V, Brinkkemper M, Capella-Pujol J, Schriek AI, Torres JL, Bangaru S, Burger JA, Poniman M, Bontjer I, Bouhuijs JH, Gideonse D, Eggink D, Ward AB, Heck AJR, Van Gils MJ, Sanders RW, Schinkel J. iScience 26 106540 (2023)
  365. Combinatorial immune refocusing within the influenza hemagglutinin RBD improves cross-neutralizing antibody responses. Dosey A, Ellis D, Boyoglu-Barnum S, Syeda H, Saunders M, Watson MJ, Kraft JC, Pham MN, Guttman M, Lee KK, Kanekiyo M, King NP. Cell Rep 42 113553 (2023)
  366. Comparison of DNA vaccines with AS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2. Neeli P, Chai D, Wang X, Sobhani N, Udeani G, Li Y. iScience 26 107120 (2023)
  367. Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review. Lee JK, Shin OS. J Yeungnam Med Sci 39 89-97 (2022)
  368. Cryoelectron microscopy structures of a human neutralizing antibody bound to MERS-CoV spike glycoprotein. Zhang S, Jia W, Zeng J, Li M, Wang Z, Zhou H, Zhang L, Wang X. Front Microbiol 13 988298 (2022)
  369. Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies. Qiu H, Yuan XY, Cabral T, Manguiat K, Robinson A, Wood H, Grant C, McQueen P, Westmacott G, Beniac DR, Lin L, Carpenter M, Kobasa D, Gräfenhan T. Antiviral Res 196 105206 (2021)
  370. Discovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variants. Hollingsworth SA, Noland CL, Vroom K, Saha A, Sam M, Gao Q, Zhou H, Grandy DU, Singh S, Wen Z, Warren C, Ma XS, Malashock D, Galli J, Go G, Eddins M, Mayhood T, Sathiyamoorthy K, Fridman A, Raoufi F, Gomez-Llorente Y, Patridge A, Tang Y, Chen SJ, Bailly M, Ji C, Kingsley LJ, Cheng AC, Geierstanger BH, Gorman DM, Zhang L, Pande K. Sci Rep 13 13668 (2023)
  371. Efficacy of a plant-produced infectious bronchitis virus-like particle vaccine in specific pathogen-free chickens. Sepotokele KM, O'Kennedy MM, Hayes MC, Wandrag DBR, Smith P, Abolnik C. Poult Sci 102 102953 (2023)
  372. Functional profiling of Covid 19 vaccine candidate by flow virometry. Prout A, Rustandi RR, Tubbs C, Winters MA, McKenna P, Vlasak J. Vaccine 40 5529-5536 (2022)
  373. Gag Virus-like Particles Functionalized with SARS-CoV-2 Variants: Generation, Characterization and Recognition by COVID-19 Convalescent Patients' Sera. Boix-Besora A, Gòdia F, Cervera L. Vaccines (Basel) 11 1641 (2023)
  374. High-Accuracy Prediction of Stabilizing Surface Mutations to the Three-Helix Bundle, UBA(1), with EmCAST. Rothfuss MT, Becht DC, Zeng B, McClelland LJ, Yates-Hansen C, Bowler BE. J Am Chem Soc 145 22979-22992 (2023)
  375. Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization. Hauser BM, Sangesland M, Lam EC, Feldman J, Balazs AB, Lingwood D, Schmidt AG. Front Immunol 13 902260 (2022)
  376. LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters. de Moor WRJ, Williamson AL, Schäfer G, Douglass N, Gers S, Sutherland AD, Blumenthal MJ, Margolin E, Shaw ML, Preiser W, Chapman R. Viruses 15 1409 (2023)
  377. Lack of effects on female fertility or pre- and postnatal development of offspring in rats after exposure to AS03-adjuvanted recombinant plant-derived virus-like particle vaccine candidate for COVID-19. Dubé C, Paris-Robidas S, Primakova I, Destexhe E, Ward BJ, Landry N, Trépanier S. Reprod Toxicol 107 69-80 (2022)
  378. Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses. Vzorov AN, Samokhvalov EI, Chebanenko VV, Scheblyakov DV, Gintsburg AL. Mol Biol 55 538-547 (2021)
  379. Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant. Ávila-Nieto C, Vergara-Alert J, Amengual-Rigo P, Ainsua-Enrich E, Brustolin M, Rodríguez de la Concepción ML, Pedreño-Lopez N, Rodon J, Urrea V, Pradenas E, Marfil S, Ballana E, Riveira-Muñoz E, Pérez M, Roca N, Tarrés-Freixas F, Carabelli J, Cantero G, Pons-Grífols A, Rovirosa C, Aguilar-Gurrieri C, Ortiz R, Barajas A, Trinité B, Lepore R, Muñoz-Basagoiti J, Perez-Zsolt D, Izquierdo-Useros N, Valencia A, Blanco J, Clotet B, Guallar V, Segalés J, Carrillo J. Front Immunol 14 1291972 (2023)
  380. Optimization of infectious bronchitis virus-like particle expression in Nicotiana benthamiana as potential poultry vaccines. Sepotokele KM, O'Kennedy MM, Wandrag DBR, Abolnik C. PLoS One 18 e0288970 (2023)
  381. SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN®, induces robust humoral and cellular immunity in mice and non-human primates. Alimohammadi R, Porgoo M, Eftekhary M, Kiaie SH, Ansari Dezfouli E, Dehghani M, Nasrollahi K, Malekshahabi T, Heidari M, Pouya S, Alimohammadi M, Sattari Khavas D, Modaresi MS, Ghasemi MH, Ramyar H, Mohammadipour F, Hamzelouei F, Mofayezi A, Mottaghi SS, Rahmati A, Razzaznian M, Tirandazi V, Tat M, Borzouee F, Sadeghi H, Haji Mohammadi M, Rastegar L, Safar Sajadi SM, Ehsanbakhsh H, Bazmbar H, Baghernejadan Z, Shams Nouraei M, Pazooki P, Pahlavanneshan M, Alishah K, Nasiri F, Mokhberian N, Mohammadi SS, Akar S, Niknam H, Azizi M, Ajoudanian M, Moteallehi-Ardakani MH, Mousavi Shaegh SA, Ramezani R, Salimi V, Moazzami R, Hashemi SM, Dehghanizadeh S, Khoddami V. NPJ Vaccines 7 105 (2022)
  382. Selective reversed-phase high-performance liquid chromatography method for the determination of intact SARS-CoV-2 spike protein. Lorbetskie B, White T, Creskey M, Zhang X, Girard M, Tam RY, Sauvé S, Lu H. J Chromatogr A 1680 463424 (2022)
  383. Soluble SARS-CoV-2 RBD and human ACE2 peptidase domain produced in Drosophila S2 cells show functions evoking virus-cell interface. Carrión F, Rammauro F, Olivero-Deibe N, Fló M, Portela MM, Lima A, Durán R, Pritsch O, Bianchi S. Protein Sci 32 e4721 (2023)
  384. Spike protein mutational landscape in India during the complete lockdown phase: Could Muller's ratchet be a future game-changer for COVID-19? Banerjee R, Basak K, Ghosh A, Rajachandran V, Sureka K, Ganguly D, Chattopadhyay S. Infect Genet Evol 92 104874 (2021)
  385. Spike substitution T813S increases Sarbecovirus fusogenicity by enhancing the usage of TMPRSS2. Ma Y, Li P, Hu Y, Qiu T, Wang L, Lu H, Lv K, Xu M, Zhuang J, Liu X, He S, He B, Liu S, Liu L, Wang Y, Yue X, Zhai Y, Luo W, Mai H, Kuang Y, Chen S, Ye F, Zhou N, Zhao W, Chen J, Chen S, Xiong X, Shi M, Pan JA, Chen YQ. PLoS Pathog 19 e1011123 (2023)
  386. News Stalking new vaccines: Methods that target the stems of viral proteins could put universal vaccines within reach. Arnold C. Nat Med 23 1248-1250 (2017)
  387. Structural Design and Assessing of Recombinantly Expressed African Swine Fever Virus p72 Trimer in Saccharomyces cerevisiae. Meng K, Zhang Y, Liu Q, Huyan Y, Zhu W, Xiang Y, Meng G. Front Microbiol 13 802098 (2022)
  388. Structure and epitope of a neutralizing monoclonal antibody that targets the stem helix of β coronaviruses. Deshpande A, Schormann N, Piepenbrink MS, Martinez Sobrido L, Kobie JJ, Walter MR. FEBS J 290 3422-3435 (2023)
  389. Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2. Zhang T, Zheng N, Wang Z, Xu X. Hum Vaccin Immunother 19 2174755 (2023)
  390. Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases. Xu Z, Ho M, Bordoloi D, Kudchodkar S, Khoshnejad M, Giron L, Zaidi F, Jeong M, Roberts CC, Park YK, Maslow J, Abdel-Mohsen M, Muthumani K. Methods Mol Biol 2410 229-263 (2022)
  391. Thiopurines inhibit coronavirus Spike protein processing and incorporation into progeny virions. Pringle ES, Duguay BA, Bui-Marinos MP, Mulloy RP, Landreth SL, Desireddy KS, Dolliver SM, Ying S, Caddell T, Tooley TH, Slaine PD, Bearne SL, Falzarano D, Corcoran JA, Khaperskyy DA, McCormick C. PLoS Pathog 18 e1010832 (2022)
  392. mRNA COVID-19 Vaccines-Facts and Hypotheses on Fragmentation and Encapsulation. Demongeot J, Fougère C. Vaccines (Basel) 11 40 (2022)
  393. A Candidate DNA Vaccine Encoding the Native SARS-CoV-2 Spike Protein Induces Anti-Subdomain 1 Antibodies. Frische A, Gunalan V, Krogfelt KA, Fomsgaard A, Lassaunière R. Vaccines (Basel) 11 1451 (2023)
  394. A Network Pharmacology and Molecular-Docking-Based Approach to Identify the Probable Targets of Short-Chain Fatty-Acid-Producing Microbial Metabolites against Kidney Cancer and Inflammation. Karim MR, Morshed MN, Iqbal S, Mohammad S, Mathiyalagan R, Yang DC, Kim YJ, Song JH, Yang DU. Biomolecules 13 1678 (2023)
  395. A general computational design strategy for stabilizing viral class I fusion proteins. Gonzalez KJ, Huang J, Criado MF, Banerjee A, Tompkins SM, Mousa JJ, Strauch EM. Nat Commun 15 1335 (2024)
  396. A guide on how to work in vaccine science. Fleming N. Nature 599 S1-S3 (2021)
  397. A novel CpG ODN compound adjuvant enhances immune response to spike subunit vaccines of porcine epidemic diarrhea virus. Wang Y, Liu S, Li B, Sun X, Pan Q, Zheng Y, Liu J, Zhao Y, Wang J, Liu L, Du E. Front Immunol 15 1336239 (2024)
  398. Aerosol Inhalation of Chimpanzee Adenovirus Vectors (ChAd68) Expressing Ancestral or Omicron BA.1 Stabilized Pre-Fusion Spike Glycoproteins Protects Non-Human Primates against SARS-CoV-2 Infection. Wang S, Qin M, Xu L, Mu T, Zhao P, Sun B, Wu Y, Song L, Wu H, Wang W, Liu X, Li Y, Yang F, Xu K, He Z, Klein M, Wu K. Vaccines (Basel) 11 1427 (2023)
  399. Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein. Xiang J, Su J, Lan Q, Zhao W, Zhou Y, Xu Y, Niu J, Xia S, Qi Q, Sidhu S, Lu L, Miersch S, Yang B. Commun Biol 5 1179 (2022)
  400. Association of KIR Genes with Middle East Respiratory Syndrome Coronavirus Infection in South Koreans. Baek IC, Choi EJ, Kim HJ, Choi H, Shin HS, Lim DG, Kim TG. J Clin Med 13 258 (2024)
  401. Biophysical and structural characterizations of the effects of mutations on the structure-activity relationships of SARS-CoV-2 spike protein. Yu PY, Yang TJ, Hsu SD. Methods Enzymol 675 299-321 (2022)
  402. COVID-19 Vaccine-Induced Lichenoid Eruptions-Clinical and Histopathologic Spectrum in a Case Series of Fifteen Patients with Review of the Literature. Sapadin YK, Mermelstein E, Phelps RG, Basler CF, Tufariello JM, Lebwohl MG. Vaccines (Basel) 11 438 (2023)
  403. Catching the breadth of broadly protective antibodies to SARS-CoV-2. McCarthy KR. Nat Immunol 23 828-829 (2022)
  404. Design, structure and plasma binding of ancestral β-CoV scaffold antigens. Hueting D, Schriever K, Sun R, Vlachiotis S, Zuo F, Du L, Persson H, Hofström C, Ohlin M, Walldén K, Buggert M, Hammarström L, Marcotte H, Pan-Hammarström Q, Andréll J, Syrén PO. Nat Commun 14 6527 (2023)
  405. Designed nanoparticles elicit cross-reactive antibody responses to conserved influenza virus hemagglutinin stem epitopes. McCraw DM, Myers ML, Gulati NM, Prabhakaran M, Brand J, Andrews S, Gallagher JR, Maldonado-Puga S, Kim AJ, Torian U, Syeda H, Boyoglu-Barnum S, Kanekiyo M, McDermott AB, Harris AK. PLoS Pathog 19 e1011514 (2023)
  406. Disulfide stabilization reveals conserved dynamic features between SARS-CoV-1 and SARS-CoV-2 spikes. Zhang X, Li Z, Zhang Y, Liu Y, Wang J, Liu B, Chen Q, Wang Q, Fu L, Wang P, Zhong X, Jin L, Yan Q, Chen L, He J, Zhao J, Xiong X. Life Sci Alliance 6 e202201796 (2023)
  407. Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants. Mittal N, Kumar S, Rajmani RS, Singh R, Lemoine C, Jakob V, Bj S, Jagannath N, Bhat M, Chakraborty D, Pandey S, Jory A, Sa SS, Kleanthous H, Dubois P, Ringe RP, Varadarajan R. NPJ Vaccines 8 161 (2023)
  408. Enhanced stability of the SARS CoV-2 spike glycoprotein following modification of an alanine cavity in the protein core. Poumbourios P, Langer C, Boo I, Zakir T, Center RJ, Akerman A, Milogiannakis V, Aggarwal A, Johnstone BA, Ha J, Coulibaly F, Turville SG, Drummer HE. PLoS Pathog 19 e1010981 (2023)
  409. Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen. Swart M, Kuipers H, Milder F, Jongeneelen M, Ritschel T, Tolboom J, Muchene L, van der Lubbe J, Izquierdo Gil A, Veldman D, Huizingh J, Verspuij J, Schmit-Tillemans S, Blokland S, de Man M, Roozendaal R, Fox CB, Schuitemaker H, Capelle M, Langedijk JPM, Zahn R, Brandenburg B. NPJ Vaccines 8 176 (2023)
  410. Heterologous Sarbecovirus Receptor Binding Domains as Scaffolds for SARS-CoV-2 Receptor Binding Motif Presentation. Hauser BM, Sangesland M, Lam EC, St Denis KJ, Sheehan ML, Vu ML, Cheng AH, Sordilla S, Lamson DT, Almawi AW, Balazs AB, Lingwood D, Schmidt AG. ACS Infect Dis 10 553-561 (2024)
  411. Influence of variant-specific mutations, temperature and pH on conformations of a large set of SARS-CoV-2 spike trimer vaccine antigen candidates. Stuible M, Schrag JD, Sheff J, Zoubchenok D, Lord-Dufour S, Cass B, L'Abbé D, Pelletier A, Rossotti MA, Tanha J, Gervais C, Maurice R, El Bakkouri M, Acchione M, Durocher Y. Sci Rep 13 16498 (2023)
  412. Interrogating ligand-receptor interactions using highly sensitive cellular biosensors. Funk MA, Leitner J, Gerner MC, Hammerler JM, Salzer B, Lehner M, Battin C, Gumpelmair S, Stiasny K, Grabmeier-Pfistershammer K, Steinberger P. Nat Commun 14 7804 (2023)
  413. Lessons learned from urgent computing in Europe: Tackling the COVID-19 pandemic. López N, Del Debbio L, Baaden M, Praprotnik M, Grigori L, Simões C, Bogaerts S, Berberich F, Lippert T, Ignatius J, Lavocat P, Pineda O, Giuffreda MG, Girona S, Kranzlmüller D, Resch MM, Scipione G, Schulthess T. Proc Natl Acad Sci U S A 118 e2024891118 (2021)
  414. PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application. Zhang Z, Zhou J, Ni P, Hu B, Jolicoeur N, Deng S, Xiao Q, He Q, Li G, Xia Y, Liu M, Wang C, Fang Z, Xia N, Zhang ZR, Zhang B, Cai K, Xu Y, Liu B. NPJ Vaccines 8 38 (2023)
  415. Pandemics and the English Language: Concepts Critical for Conversing About COVID-19. Greenspan NS, Pereda GA. Pathog Immun 7 78-92 (2022)
  416. Prefusion stabilization of the Hendra and Langya virus F proteins. Byrne PO, Blade EG, Fisher BE, Ambrozak DR, Ramamohan AR, Graham BS, Loomis RJ, McLellan JS. J Virol 98 e0137223 (2024)
  417. Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge. Hsieh CL, Leist SR, Miller EH, Zhou L, Powers JM, Tse AL, Wang A, West A, Zweigart MR, Schisler JC, Jangra RK, Chandran K, Baric RS, McLellan JS. Nat Commun 15 1553 (2024)
  418. Prepandemic Preparedness under the Spotlight at ASGCT's COVID-19 Symposium. Dolgin E. Mol Ther 28 2310-2313 (2020)
  419. Revealing Novel-Strain-Specific and Shared Epitopes of Infectious Bronchitis Virus Spike Glycoprotein Using Chemical Linkage of Peptides onto Scaffolds Precision Epitope Mapping. Sives S, Keep S, Bickerton E, Vervelde L. Viruses 15 2279 (2023)
  420. Secondary Structures of MERS-CoV, SARS-CoV, and SARS-CoV-2 Spike Proteins Revealed by Infrared Vibrational Spectroscopy. D'Arco A, Di Fabrizio M, Mancini T, Mosetti R, Macis S, Tranfo G, Della Ventura G, Marcelli A, Petrarca M, Lupi S. Int J Mol Sci 24 9550 (2023)
  421. Single Amino Acid Substitution in the Receptor Binding Domain of Spike Protein Is Sufficient To Convert the Neutralization Profile between Ethiopian and Middle Eastern Isolates of Middle East Respiratory Coronavirus. Sugimoto S, Kakizaki M, Kawase M, Kawachi K, Ujike M, Kamitani W, Sentsui H, Shirato K. Microbiol Spectr e0459022 (2023)
  422. Stabilization of the Metastable Pre-Fusion Conformation of the SARS-CoV-2 Spike Glycoprotein through N-Linked Glycosylation of the S2 Subunit. Zan F, Zhou Y, Chen T, Chen Y, Mu Z, Qian Z, Ou X. Viruses 16 223 (2024)
  423. Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2. Bruch EM, Zhu S, Szymkowicz L, Blake T, Kiss T, James DA, Rak A, Narayan K, Balmer MT, Chicz RM. Sci Rep 14 2038 (2024)
  424. Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity. Muñoz-Alía MÁ, Nace RA, Balakrishnan B, Zhang L, Packiriswamy N, Singh G, Warang P, Mena I, Narjari R, Vandergaast R, Peng K-W, García-Sastre A, Schotsaert M, Russell SJ. mBio 15 e0292823 (2024)
  425. Systemic Neutralizing Antibodies and Local Immune Responses Are Critical for the Control of SARS-CoV-2. Chandrasekar SS, Phanse Y, Riel M, Hildebrand RE, Hanafy M, Osorio JE, Abdelgayed SS, Talaat AM. Viruses 14 1262 (2022)
  426. THE GORDON WILSON LECTURE: RAPID COVID-19 VACCINE DEVELOPMENT AND THE FUTURE OF VACCINOLOGY. Graham BS. Trans Am Clin Climatol Assoc 133 103-105 (2023)
  427. Targeted mutagenesis of the herpesvirus fusogen central helix captures transition states. Zhou M, Vollmer B, Machala E, Chen M, Grünewald K, Arvin AM, Chiu W, Oliver SL. Nat Commun 14 7958 (2023)
  428. The post-COVID-19 population has a high prevalence of cross-reactive antibodies to spikes from all Orthocoronavirinae genera. Singh G, Abbad A, Kleiner G, Srivastava K, Gleason C, PARIS Study Group, Carreño JM, Simon V, Krammer F. mBio 15 e0225023 (2024)
  429. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope. McCool RS, Musayev M, Bush SM, Derrien-Colemyn A, Acreman CM, Wrapp D, Ruckwardt TJ, Graham BS, Mascola JR, McLellan JS. J Virol 97 e0092923 (2023)
  430. Viral Prototypes for Pandemic Preparedness: The Road Ahead. Morabito KM, Cassetti MC, DeRocco AJ, Deschamps AM, Pierson TC. J Infect Dis 228 S460-S464 (2023)
  431. Why would a black man volunteer for a government-funded science experiment? Nduom EK. EClinicalMedicine 33 100788 (2021)
  432. [Progress on the development of the SARS-CoV-2 vaccine and antibody drugs]. Xu S, Tang D. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 39 1059-1064 (2022)


Quick links